[
  {
    "symbol": "VERA",
    "timestamp": "2024-11-17 14:45:40",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 46.27,
    "priceChange": -5.57,
    "openPrice": 49.29,
    "prevClose": 49.0,
    "dayHigh": 49.31,
    "dayLow": 45.64,
    "volume": 909700,
    "prevVolume": 642800,
    "averageVolume": 676315.5555555555,
    "volumeChange": 41.52,
    "volumeVsAvg": 34.51,
    "recentVolumes": [
      658700,
      545100,
      1004300,
      642800,
      909700
    ],
    "marketCap": 2929326592,
    "fiftyTwoWeekHigh": 51.61,
    "fiftyTwoWeekLow": 12.28,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-11 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/vera-therapeutics-reports-inducement-grants-210500816.html"
      },
      {
        "title": "Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet",
        "publisher": "Zacks",
        "timestamp": "2024-11-11 06:55:12",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/wall-street-analysts-think-vera-145512586.html"
      },
      {
        "title": "Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-11 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/vera-therapeutics-partners-university-michigan-130000119.html"
      },
      {
        "title": "Vera Therapeutics to Participate at Upcoming Investor Conferences",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-08 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/vera-therapeutics-participate-upcoming-investor-210500989.html"
      },
      {
        "title": "Wedbush Raises Vera Therapeutics' Price Target to $38 From $30, Maintains Neutral rating",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-08 04:11:35",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/wedbush-raises-vera-therapeutics-apos-121135607.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ANIX",
    "timestamp": "2024-11-17 14:45:41",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 3.08,
    "priceChange": -1.6,
    "openPrice": 3.15,
    "prevClose": 3.13,
    "dayHigh": 3.18,
    "dayLow": 3.05,
    "volume": 110400,
    "prevVolume": 81100,
    "averageVolume": 99136.66666666667,
    "volumeChange": 36.13,
    "volumeVsAvg": 11.36,
    "recentVolumes": [
      165600,
      139900,
      74300,
      81100,
      110400
    ],
    "marketCap": 99112856,
    "fiftyTwoWeekHigh": 5.13,
    "fiftyTwoWeekLow": 2.15,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting",
        "publisher": "PR Newswire",
        "timestamp": "2024-11-08 10:17:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/anixa-biosciences-cleveland-clinic-present-181700149.html"
      },
      {
        "title": "Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting",
        "publisher": "PR Newswire",
        "timestamp": "2024-11-06 05:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/anixa-biosciences-announces-timing-public-133000341.html"
      },
      {
        "title": "Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024",
        "publisher": "PR Newswire",
        "timestamp": "2024-10-31 05:15:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/anixa-biosciences-present-sidoti-micro-121500921.html"
      },
      {
        "title": "Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting",
        "publisher": "PR Newswire",
        "timestamp": "2024-10-28 05:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/anixa-biosciences-cleveland-clinic-present-123000699.html"
      },
      {
        "title": "US Penny Stocks To Consider In October 2024",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-10-24 13:06:45",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/us-penny-stocks-consider-october-200645752.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "INMB",
    "timestamp": "2024-11-17 14:45:42",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 4.96,
    "priceChange": -8.82,
    "openPrice": 5.31,
    "prevClose": 5.44,
    "dayHigh": 5.34,
    "dayLow": 4.91,
    "volume": 388200,
    "prevVolume": 146000,
    "averageVolume": 223581.11111111112,
    "volumeChange": 165.89,
    "volumeVsAvg": 73.63,
    "recentVolumes": [
      122200,
      209800,
      181200,
      146000,
      388200
    ],
    "marketCap": 109864736,
    "fiftyTwoWeekHigh": 14.74,
    "fiftyTwoWeekLow": 4.78,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-13 06:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/inmune-bio-inc-announces-final-140000415.html"
      },
      {
        "title": "INmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023)",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-03 05:31:38",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/inmune-bio-third-quarter-2024-133138980.html"
      },
      {
        "title": "INmune Bio Inc (INMB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-01 08:01:25",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/inmune-bio-inc-inmb-q3-150125116.html"
      },
      {
        "title": "INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-31 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/inmune-bio-inc-announces-third-200500239.html"
      },
      {
        "title": "INmune Bio Inc (INMB) Q3 2024 Earnings Report Preview: What To Look For",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-10-30 06:22:23",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/inmune-bio-inc-inmb-q3-132223934.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 5,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "GUTS",
    "timestamp": "2024-11-17 14:45:42",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 1.96,
    "priceChange": -6.22,
    "openPrice": 2.14,
    "prevClose": 2.09,
    "dayHigh": 2.14,
    "dayLow": 1.92,
    "volume": 381000,
    "prevVolume": 490700,
    "averageVolume": 372575.55555555556,
    "volumeChange": -22.36,
    "volumeVsAvg": 2.26,
    "recentVolumes": [
      410500,
      432900,
      375000,
      490700,
      381000
    ],
    "marketCap": 94514344,
    "fiftyTwoWeekHigh": 14.5,
    "fiftyTwoWeekLow": 1.74,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Fractyl Health Third Quarter 2024 Earnings: US$0.48 loss per share (vs US$9.61 loss in 3Q 2023)",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-14 04:08:03",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/fractyl-health-third-quarter-2024-120803679.html"
      },
      {
        "title": "Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-12 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/fractyl-health-reports-third-quarter-210500420.html"
      },
      {
        "title": "Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva\u00ae RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek\u00ae 2024",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-04 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/fractyl-health-present-preclinical-data-210500907.html"
      },
      {
        "title": "Fractyl Health Presented New Analysis from Pooled Data of Revita\u00ae Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek\u00ae 2024",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-04 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/fractyl-health-presented-analysis-pooled-120000595.html"
      },
      {
        "title": "Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-29 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/fractyl-health-report-third-quarter-110000231.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "MIRA",
    "timestamp": "2024-11-17 14:45:43",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "price": 1.54,
    "priceChange": 2.67,
    "openPrice": 1.5,
    "prevClose": 1.5,
    "dayHigh": 1.56,
    "dayLow": 1.47,
    "volume": 243600,
    "prevVolume": 334800,
    "averageVolume": 4884168.888888889,
    "volumeChange": -27.24,
    "volumeVsAvg": -95.01,
    "recentVolumes": [
      889700,
      618200,
      666400,
      334800,
      243600
    ],
    "marketCap": 25049794,
    "fiftyTwoWeekHigh": 6.4,
    "fiftyTwoWeekLow": 0.51,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "MIRA Continues Solid Financial Management",
        "publisher": "Zacks Small Cap Research",
        "timestamp": "2024-11-13 03:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mira-continues-solid-financial-management-110000117.html"
      },
      {
        "title": "MIRA Pharmaceuticals Shares Surge 40% After Ketamir-2 Excels in Pain Management Trials",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-10-29 07:57:44",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mira-pharmaceuticals-shares-surge-40-145744961.html"
      },
      {
        "title": "MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain",
        "publisher": "Benzinga",
        "timestamp": "2024-10-28 10:41:01",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mira-pharmaceuticals-formulated-shows-greater-174058339.html"
      },
      {
        "title": "MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain",
        "publisher": "ACCESSWIRE",
        "timestamp": "2024-10-28 04:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mira-pharmaceuticals-ketamir-2-shows-113000711.html"
      },
      {
        "title": "Weekly Roundup on the Cannabis Sector & Psychedelic Sector 10-28-2024",
        "publisher": "Market Exclusive",
        "timestamp": "2024-10-27 14:34:04",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/weekly-roundup-cannabis-sector-psychedelic-213404393.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "EYPT",
    "timestamp": "2024-11-17 14:45:44",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 9.17,
    "priceChange": -12.58,
    "openPrice": 10.56,
    "prevClose": 10.49,
    "dayHigh": 10.56,
    "dayLow": 9.05,
    "volume": 1017700,
    "prevVolume": 795000,
    "averageVolume": 742645.5555555555,
    "volumeChange": 28.01,
    "volumeVsAvg": 37.04,
    "recentVolumes": [
      548100,
      630600,
      739200,
      795000,
      1017700
    ],
    "marketCap": 625861696,
    "fiftyTwoWeekHigh": 30.99,
    "fiftyTwoWeekLow": 5.86,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High?",
        "publisher": "Zacks",
        "timestamp": "2024-11-13 06:55:10",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/wall-street-analysts-see-175-145510736.html"
      },
      {
        "title": "EyePoint price target lowered to $33 from $38 at Baird",
        "publisher": "TipRanks",
        "timestamp": "2024-11-12 03:45:45",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/eyepoint-price-target-lowered-33-114545856.html"
      },
      {
        "title": "EyePoint Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-09 05:04:42",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/eyepoint-pharmaceuticals-third-quarter-2024-130442891.html"
      },
      {
        "title": "EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates",
        "publisher": "Zacks",
        "timestamp": "2024-11-07 05:35:06",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/eyepoint-pharmaceuticals-eypt-reports-q3-133506618.html"
      },
      {
        "title": "EyePoint Pharmaceuticals: Q3 Earnings Snapshot",
        "publisher": "Associated Press Finance",
        "timestamp": "2024-11-07 04:37:22",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/eyepoint-pharmaceuticals-q3-earnings-snapshot-123722471.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "GNPX",
    "timestamp": "2024-11-17 14:45:44",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 1.6,
    "priceChange": -2.74,
    "openPrice": 1.69,
    "prevClose": 1.64,
    "dayHigh": 1.69,
    "dayLow": 1.54,
    "volume": 742700,
    "prevVolume": 988400,
    "averageVolume": 6783400.0,
    "volumeChange": -24.86,
    "volumeVsAvg": -89.05,
    "recentVolumes": [
      725000,
      21708500,
      2755300,
      988400,
      742700
    ],
    "marketCap": 4141680,
    "fiftyTwoWeekHigh": 14.4,
    "fiftyTwoWeekLow": 0.28,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Genprex Reports Positive Preclinical Data on Reqorsa Gene Therapy; Regains Nasdaq Compliance",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-05 09:19:13",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/genprex-reports-positive-preclinical-data-171913779.html"
      },
      {
        "title": "Genprex Collaborators Present Positive Preclinical Data on Reqorsa\u00ae Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting",
        "publisher": "PR Newswire",
        "timestamp": "2024-11-05 06:29:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/genprex-collaborators-present-positive-preclinical-142900210.html"
      },
      {
        "title": "Genprex to Participate in 2024 BIO Europe Conference",
        "publisher": "PR Newswire",
        "timestamp": "2024-10-31 06:29:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/genprex-participate-2024-bio-europe-132900558.html"
      },
      {
        "title": "Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa\u00ae Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma",
        "publisher": "PR Newswire",
        "timestamp": "2024-10-28 06:29:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/genprex-collaborators-present-positive-preclinical-132900635.html"
      },
      {
        "title": "Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive",
        "publisher": "PR Newswire",
        "timestamp": "2024-10-24 06:29:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/genprex-announces-sponsored-research-agreement-132900687.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "GLUE",
    "timestamp": "2024-11-17 14:45:45",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 7.75,
    "priceChange": -8.61,
    "openPrice": 8.57,
    "prevClose": 8.48,
    "dayHigh": 8.63,
    "dayLow": 7.65,
    "volume": 880400,
    "prevVolume": 739700,
    "averageVolume": 1592572.2222222222,
    "volumeChange": 19.02,
    "volumeVsAvg": -44.72,
    "recentVolumes": [
      1726700,
      1376000,
      670600,
      739700,
      880400
    ],
    "marketCap": 475520032,
    "fiftyTwoWeekHigh": 12.4,
    "fiftyTwoWeekLow": 2.91,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet",
        "publisher": "Zacks",
        "timestamp": "2024-11-15 06:55:10",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/wall-street-analysts-think-monte-145510726.html"
      },
      {
        "title": "Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-13 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/monte-rosa-therapeutics-participate-jefferies-120000205.html"
      },
      {
        "title": "Owning 47% shares,institutional owners seem interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE),",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-11 04:45:38",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/owning-47-shares-institutional-owners-124538176.html"
      },
      {
        "title": "Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates",
        "publisher": "Zacks",
        "timestamp": "2024-11-07 05:35:06",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/monte-rosa-therapeutics-glue-reports-133506362.html"
      },
      {
        "title": "Monte Rosa Therapeutics: Q3 Earnings Snapshot",
        "publisher": "Associated Press Finance",
        "timestamp": "2024-11-07 04:30:14",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/monte-rosa-therapeutics-q3-earnings-123014078.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "TGTX",
    "timestamp": "2024-11-17 14:45:45",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 29.51,
    "priceChange": -4.33,
    "openPrice": 30.61,
    "prevClose": 30.84,
    "dayHigh": 31.24,
    "dayLow": 28.91,
    "volume": 3272400,
    "prevVolume": 8163300,
    "averageVolume": 3637656.6666666665,
    "volumeChange": -59.91,
    "volumeVsAvg": -10.04,
    "recentVolumes": [
      5341600,
      5493000,
      9890800,
      8163300,
      3272400
    ],
    "marketCap": 4598344192,
    "fiftyTwoWeekHigh": 36.5,
    "fiftyTwoWeekLow": 11.86,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Exploring 3 High Growth Tech Stocks in the United States",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-12 06:09:17",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/exploring-3-high-growth-tech-140917343.html"
      },
      {
        "title": "TG Therapeutics, Inc. Just Missed Earnings - But Analysts Have Updated Their Models",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-07 04:13:19",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/tg-therapeutics-inc-just-missed-121319793.html"
      },
      {
        "title": "TG Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-05 02:41:03",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/tg-therapeutics-third-quarter-2024-104103941.html"
      },
      {
        "title": "TG Therapeutics Inc (TGTX) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-04 23:02:21",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/tg-therapeutics-inc-tgtx-q3-070221436.html"
      },
      {
        "title": "Q3 2024 TG Therapeutics Inc Earnings Call",
        "publisher": "Thomson Reuters StreetEvents",
        "timestamp": "2024-11-04 22:17:11",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/q3-2024-tg-therapeutics-inc-061711782.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "AUPH",
    "timestamp": "2024-11-17 14:45:46",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 8.12,
    "priceChange": -2.52,
    "openPrice": 8.36,
    "prevClose": 8.33,
    "dayHigh": 8.39,
    "dayLow": 8.07,
    "volume": 1444500,
    "prevVolume": 1406500,
    "averageVolume": 1329381.111111111,
    "volumeChange": 2.7,
    "volumeVsAvg": 8.66,
    "recentVolumes": [
      1961300,
      1551800,
      1579100,
      1406500,
      1444500
    ],
    "marketCap": 1162613504,
    "fiftyTwoWeekHigh": 10.05,
    "fiftyTwoWeekLow": 4.71,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS\u00ae in Managing LN at American College of Rheumatology Convergence 2024",
        "publisher": "Business Wire",
        "timestamp": "2024-11-15 03:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/aurinia-presents-data-underscoring-critical-110000086.html"
      },
      {
        "title": "Aurinia to Participate in Jefferies London Healthcare Conference",
        "publisher": "Business Wire",
        "timestamp": "2024-11-14 03:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/aurinia-participate-jefferies-london-healthcare-110000160.html"
      },
      {
        "title": "RBC Adjusts Aurinia Pharmaceuticals' Price Target to $9 From $8, Keeps Outperform Speculative Risk Rating",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-11 05:32:39",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/rbc-adjusts-aurinia-pharmaceuticals-apos-133239726.html"
      },
      {
        "title": "Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets",
        "publisher": "Pharmaceutical Technology",
        "timestamp": "2024-11-08 07:30:56",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/652535ca-16df-3e59-8c10-f9726d14b317/aurinia-slashes-workforce-by.html"
      },
      {
        "title": "Aurinia Pharmaceuticals Reports Strong Q3 Growth and Restructuring",
        "publisher": "TipRanks",
        "timestamp": "2024-11-08 03:37:45",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/aurinia-pharmaceuticals-reports-strong-q3-113745904.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ITCI",
    "timestamp": "2024-11-17 14:45:46",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "price": 83.41,
    "priceChange": -4.82,
    "openPrice": 86.0,
    "prevClose": 87.63,
    "dayHigh": 86.85,
    "dayLow": 83.21,
    "volume": 628200,
    "prevVolume": 616300,
    "averageVolume": 607342.2222222222,
    "volumeChange": 1.93,
    "volumeVsAvg": 3.43,
    "recentVolumes": [
      922100,
      791600,
      982100,
      616300,
      628200
    ],
    "marketCap": 8843937792,
    "fiftyTwoWeekHigh": 93.45,
    "fiftyTwoWeekLow": 56.83,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Intra-Cellular Therapies Insider Sold Shares Worth $3,692,100, According to a Recent SEC Filing",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-15 00:51:02",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/intra-cellular-therapies-insider-sold-085102357.html"
      },
      {
        "title": "Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-07 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/intra-cellular-therapies-announces-presentations-130000256.html"
      },
      {
        "title": "Intra-Cellular bolsters Caplyta data with another Phase III win",
        "publisher": "Pharmaceutical Technology",
        "timestamp": "2024-11-06 10:07:42",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/0a44869e-61ad-3d20-ba7d-82d2e12ec64e/intra-cellular-bolsters.html"
      },
      {
        "title": "Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-05 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/intra-cellular-therapies-announces-positive-120000758.html"
      },
      {
        "title": "Here's What Analysts Are Forecasting For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) After Its Third-Quarter Results",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-02 06:33:12",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/heres-analysts-forecasting-intra-cellular-133312490.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "CLOV",
    "timestamp": "2024-11-17 14:45:47",
    "sector": "Healthcare",
    "industry": "Healthcare Plans",
    "price": 3.05,
    "priceChange": -1.14,
    "openPrice": 3.0,
    "prevClose": 3.08,
    "dayHigh": 3.08,
    "dayLow": 2.99,
    "volume": 5276700,
    "prevVolume": 6414300,
    "averageVolume": 8559892.222222222,
    "volumeChange": -17.74,
    "volumeVsAvg": -38.36,
    "recentVolumes": [
      10891200,
      8692700,
      6047000,
      6414300,
      5276700
    ],
    "marketCap": 1523371264,
    "fiftyTwoWeekHigh": 4.71,
    "fiftyTwoWeekLow": 0.61,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Clover Health Investments Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-08 02:26:36",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/clover-health-investments-third-quarter-102636584.html"
      },
      {
        "title": "Clover Health Investments Corp (CLOV) Q3 2024 Earnings Call Highlights: Strong Financial ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-07 13:01:22",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/clover-health-investments-corp-clov-210122688.html"
      },
      {
        "title": "Clover Health Reports Strong Third Quarter 2024 Financial Results; Highlights Differentiated Market Opportunity to Grow Membership",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-06 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/clover-health-reports-strong-third-210500209.html"
      },
      {
        "title": "What To Expect From Clover Health Investments Corp (CLOV) Q3 2024 Earnings",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-05 04:45:14",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/expect-clover-health-investments-corp-124514851.html"
      },
      {
        "title": "Top US Penny Stocks To Watch In October 2024",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-10-30 06:07:48",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/top-us-penny-stocks-watch-130748963.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "IPHA",
    "timestamp": "2024-11-17 14:45:50",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 1.44,
    "priceChange": -13.51,
    "openPrice": 1.6,
    "prevClose": 1.66,
    "dayHigh": 1.66,
    "dayLow": 1.44,
    "volume": 20100,
    "prevVolume": 5800,
    "averageVolume": 8147.777777777777,
    "volumeChange": 246.55,
    "volumeVsAvg": 146.69,
    "recentVolumes": [
      7400,
      8900,
      4000,
      5800,
      20100
    ],
    "marketCap": 130324472,
    "fiftyTwoWeekHigh": 3.15,
    "fiftyTwoWeekLow": 1.44,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Discover 3 Promising Penny Stocks With Over US$90M Market Cap",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-13 00:05:39",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/discover-3-promising-penny-stocks-080539708.html"
      },
      {
        "title": "Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results",
        "publisher": "Business Wire",
        "timestamp": "2024-11-12 22:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/innate-pharma-reports-third-quarter-060000039.html"
      },
      {
        "title": "Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024",
        "publisher": "Business Wire",
        "timestamp": "2024-11-07 22:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/innate-pharma-highlights-data-innovative-060000898.html"
      },
      {
        "title": "Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates",
        "publisher": "Business Wire",
        "timestamp": "2024-11-06 22:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/innate-pharma-announces-conference-call-060000946.html"
      },
      {
        "title": "Innate Pharma Announces Its Participation in Upcoming Investor Conferences",
        "publisher": "Business Wire",
        "timestamp": "2024-10-28 23:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/innate-pharma-announces-participation-upcoming-060000595.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 5,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "MDWD",
    "timestamp": "2024-11-17 14:45:51",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 16.01,
    "priceChange": -2.2,
    "openPrice": 16.4,
    "prevClose": 16.37,
    "dayHigh": 16.4,
    "dayLow": 15.76,
    "volume": 58800,
    "prevVolume": 39600,
    "averageVolume": 65253.333333333336,
    "volumeChange": 48.48,
    "volumeVsAvg": -9.89,
    "recentVolumes": [
      48200,
      27400,
      46900,
      39600,
      58800
    ],
    "marketCap": 172582400,
    "fiftyTwoWeekHigh": 24.0,
    "fiftyTwoWeekLow": 8.22,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "MediWound to Report Third Quarter 2024 Financial Results",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-12 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mediwound-report-third-quarter-2024-130000999.html"
      },
      {
        "title": "MediWound's (NASDAQ:MDWD) investors will be pleased with their stellar 125% return over the last year",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-10-27 06:17:32",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mediwounds-nasdaq-mdwd-investors-pleased-131732669.html"
      },
      {
        "title": "Rosalind Advisors, Inc. Increases Stake in MediWound Ltd",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-10-23 16:01:07",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/rosalind-advisors-inc-increases-stake-230107196.html"
      },
      {
        "title": "MediWound to Begin Phase II Study of EscharEx Versus Collagenase in Venous Leg Ulcer Patients",
        "publisher": "MT Newswires",
        "timestamp": "2024-10-10 08:07:39",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mediwound-begin-phase-ii-study-150739321.html"
      },
      {
        "title": "MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx\u00ae vs. Collagenase in Patients with Venous Leg Ulcers",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-10 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mediwound-announces-phase-ii-head-110000332.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ZYME",
    "timestamp": "2024-11-17 14:45:52",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 15.39,
    "priceChange": -5.35,
    "openPrice": 16.23,
    "prevClose": 16.26,
    "dayHigh": 16.24,
    "dayLow": 15.0,
    "volume": 628000,
    "prevVolume": 622800,
    "averageVolume": 657187.7777777778,
    "volumeChange": 0.83,
    "volumeVsAvg": -4.44,
    "recentVolumes": [
      573300,
      560700,
      395800,
      622800,
      628000
    ],
    "marketCap": 1060024832,
    "fiftyTwoWeekHigh": 17.7,
    "fiftyTwoWeekLow": 7.97,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-\u237a Expressing Advanced Solid Tumors",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-05 03:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/zymeworks-announces-first-patient-dosed-110000900.html"
      },
      {
        "title": "Zymeworks Third Quarter 2024 Earnings: Revenues Disappoint",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-02 06:53:42",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/zymeworks-third-quarter-2024-earnings-135342859.html"
      },
      {
        "title": "Zymeworks Inc. (NASDAQ:ZYME) Analysts Are Reducing Their Forecasts For Next Year",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-01 05:54:26",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/zymeworks-inc-nasdaq-zyme-analysts-125426224.html"
      },
      {
        "title": "Zymeworks Provides Corporate Update and\u00a0Reports Third Quarter 2024 Financial Results",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-31 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/zymeworks-provides-corporate-reports-third-200500097.html"
      },
      {
        "title": "Zymeworks Inc (ZYME) Q3 2024 Earnings Report Preview: What To Look For",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-10-30 06:14:39",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/zymeworks-inc-zyme-q3-2024-131439426.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ASMB",
    "timestamp": "2024-11-17 14:45:52",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 16.26,
    "priceChange": -4.63,
    "openPrice": 16.86,
    "prevClose": 17.05,
    "dayHigh": 17.03,
    "dayLow": 16.0,
    "volume": 17900,
    "prevVolume": 32200,
    "averageVolume": 23537.777777777777,
    "volumeChange": -44.41,
    "volumeVsAvg": -23.95,
    "recentVolumes": [
      31600,
      19000,
      29100,
      32200,
      17900
    ],
    "marketCap": 102590520,
    "fiftyTwoWeekHigh": 19.93,
    "fiftyTwoWeekLow": 7.68,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Bearish: Analysts Just Cut Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Revenue and EPS estimates",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-13 03:18:50",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/bearish-analysts-just-cut-assembly-111850710.html"
      },
      {
        "title": "Assembly Biosciences: Q3 Earnings Snapshot",
        "publisher": "Associated Press Finance",
        "timestamp": "2024-11-07 15:19:06",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/assembly-biosciences-q3-earnings-snapshot-231906509.html"
      },
      {
        "title": "Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-07 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/assembly-biosciences-reports-third-quarter-210500996.html"
      },
      {
        "title": "Are Medical Stocks Lagging  ADMA Biologics (ADMA) This Year?",
        "publisher": "Zacks",
        "timestamp": "2024-10-02 06:40:10",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/medical-stocks-lagging-adma-biologics-134010008.html"
      },
      {
        "title": "Assembly Biosciences' Investigational Herpes Treatment Shows Safety In Healthy Participants (UPDATED)",
        "publisher": "Benzinga",
        "timestamp": "2024-09-23 10:39:36",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/assembly-biosciences-investigational-herpes-treatment-173948990.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "JAZZ",
    "timestamp": "2024-11-17 14:45:53",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 121.62,
    "priceChange": -2.13,
    "openPrice": 122.31,
    "prevClose": 124.27,
    "dayHigh": 123.0,
    "dayLow": 120.41,
    "volume": 718200,
    "prevVolume": 914300,
    "averageVolume": 665643.3333333334,
    "volumeChange": -21.45,
    "volumeVsAvg": 7.9,
    "recentVolumes": [
      1000400,
      1035400,
      811800,
      914300,
      718200
    ],
    "marketCap": 7354301952,
    "fiftyTwoWeekHigh": 134.17,
    "fiftyTwoWeekLow": 99.06,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Is the Options Market Predicting a Spike in Jazz (JAZZ) Stock?",
        "publisher": "Zacks",
        "timestamp": "2024-11-14 05:46:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/options-market-predicting-spike-jazz-134600572.html"
      },
      {
        "title": "Jazz Pharmaceuticals' (NASDAQ:JAZZ) Performance Is Even Better Than Its Earnings Suggest",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-14 03:17:13",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/jazz-pharmaceuticals-nasdaq-jazz-performance-111713936.html"
      },
      {
        "title": "Jazz Pharmaceuticals Insider Sold Shares Worth $456,617, According to a Recent SEC Filing",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-13 14:46:31",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/jazz-pharmaceuticals-insider-sold-shares-224631987.html"
      },
      {
        "title": "Jazz (JAZZ) Upgraded to Buy: Here's Why",
        "publisher": "Zacks",
        "timestamp": "2024-11-13 09:00:11",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/jazz-jazz-upgraded-buy-heres-170011265.html"
      },
      {
        "title": "JAZZ or CTLT: Which Is the Better Value Stock Right Now?",
        "publisher": "Zacks",
        "timestamp": "2024-11-13 08:40:09",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/jazz-ctlt-better-value-stock-164009417.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "PRTA",
    "timestamp": "2024-11-17 14:45:54",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 14.0,
    "priceChange": -13.04,
    "openPrice": 16.13,
    "prevClose": 16.1,
    "dayHigh": 16.39,
    "dayLow": 14.0,
    "volume": 758500,
    "prevVolume": 469700,
    "averageVolume": 452506.6666666667,
    "volumeChange": 61.49,
    "volumeVsAvg": 67.62,
    "recentVolumes": [
      264100,
      377600,
      387300,
      469700,
      758500
    ],
    "marketCap": 753859904,
    "fiftyTwoWeekHigh": 41.55,
    "fiftyTwoWeekLow": 14.0,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe",
        "publisher": "Zacks",
        "timestamp": "2024-11-15 06:04:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/biogen-partner-eisai-gets-positive-140400531.html"
      },
      {
        "title": "Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus",
        "publisher": "Zacks",
        "timestamp": "2024-11-13 04:48:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/prothena-q3-earnings-beat-estimates-124800737.html"
      },
      {
        "title": "Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates",
        "publisher": "Zacks",
        "timestamp": "2024-11-12 14:55:10",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/prothena-prta-reports-q3-loss-225510714.html"
      },
      {
        "title": "Prothena: Q3 Earnings Snapshot",
        "publisher": "Associated Press Finance",
        "timestamp": "2024-11-12 13:56:26",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/prothena-q3-earnings-snapshot-215626131.html"
      },
      {
        "title": "Prothena Reports Third Quarter 2024 Financial Results and Business Highlights",
        "publisher": "Business Wire",
        "timestamp": "2024-11-12 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/prothena-reports-third-quarter-2024-210500834.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 5,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "TMDX",
    "timestamp": "2024-11-17 14:45:54",
    "sector": "Healthcare",
    "industry": "Medical Devices",
    "price": 80.52,
    "priceChange": -8.87,
    "openPrice": 88.93,
    "prevClose": 88.36,
    "dayHigh": 88.93,
    "dayLow": 80.06,
    "volume": 2303800,
    "prevVolume": 1467000,
    "averageVolume": 1285143.3333333333,
    "volumeChange": 57.04,
    "volumeVsAvg": 79.26,
    "recentVolumes": [
      1715800,
      1666800,
      1799200,
      1467000,
      2303800
    ],
    "marketCap": 2701029632,
    "fiftyTwoWeekHigh": 177.37,
    "fiftyTwoWeekLow": 66.76,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Is TransMedics Group Stock a Buy?",
        "publisher": "Motley Fool",
        "timestamp": "2024-11-15 05:15:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/2d04141c-29f8-3778-b4a1-de22f32d5482/is-transmedics-group-stock-a.html"
      },
      {
        "title": "Down 52%, Is TransMedics Stock a Buy on the Dip?",
        "publisher": "Motley Fool",
        "timestamp": "2024-11-09 08:07:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/4ccaa51e-9478-3697-a587-a32fd08e3a68/down-52%25%2C-is-transmedics.html"
      },
      {
        "title": "Why TransMedics Stock Plunged in October",
        "publisher": "Motley Fool",
        "timestamp": "2024-11-07 09:25:43",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/8f6a5cfa-760a-33ee-9e40-a8f314223252/why-transmedics-stock-plunged.html"
      },
      {
        "title": "1 Top Growth Stock Down 50% to Buy After Its Recent Pullback",
        "publisher": "Motley Fool",
        "timestamp": "2024-11-04 04:15:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/90e66e55-6aab-301d-ad51-bebd40a803b7/1-top-growth-stock-down-50%25.html"
      },
      {
        "title": "TransMedics (TMDX) Reports Q3 Earnings: What Key Metrics Have to Say",
        "publisher": "Zacks",
        "timestamp": "2024-10-30 06:30:45",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/transmedics-tmdx-reports-q3-earnings-133045397.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 5,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "GILD",
    "timestamp": "2024-11-17 14:45:55",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "price": 88.37,
    "priceChange": -4.06,
    "openPrice": 91.9,
    "prevClose": 92.11,
    "dayHigh": 91.98,
    "dayLow": 88.21,
    "volume": 11453600,
    "prevVolume": 8202700,
    "averageVolume": 6494618.888888889,
    "volumeChange": 39.63,
    "volumeVsAvg": 76.36,
    "recentVolumes": [
      7094300,
      9322700,
      11060500,
      8202700,
      11453600
    ],
    "marketCap": 110170267648,
    "fiftyTwoWeekHigh": 98.9,
    "fiftyTwoWeekLow": 62.07,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease",
        "publisher": "Benzinga",
        "timestamp": "2024-11-15 11:14:35",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/gilead-unveils-long-term-data-191435289.html"
      },
      {
        "title": "Gilead Sciences Says Most of Phase 3 Primary Biliary Cholangitis Participants Treated With Livdelzi Achieved Biochemical Response",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-15 08:54:12",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/gilead-sciences-says-most-phase-165412683.html"
      },
      {
        "title": "Gilead\u2019s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis",
        "publisher": "Business Wire",
        "timestamp": "2024-11-15 08:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/gilead-livdelzi-seladelpar-demonstrated-sustained-160000021.html"
      },
      {
        "title": "Wolfe Research Initiates Gilead Sciences at Outperform With $110 Price Target",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-15 03:09:17",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/wolfe-research-initiates-gilead-sciences-110917249.html"
      },
      {
        "title": "Citi initiates coverage on 5 new biotech stocks",
        "publisher": "Investing.com",
        "timestamp": "2024-11-14 06:54:44",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/citi-initiates-coverage-5-biotech-145444148.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "NTNX",
    "timestamp": "2024-11-17 14:45:56",
    "sector": "Technology",
    "industry": "Software - Infrastructure",
    "price": 69.55,
    "priceChange": -2.17,
    "openPrice": 70.0,
    "prevClose": 71.09,
    "dayHigh": 70.26,
    "dayLow": 68.96,
    "volume": 1779400,
    "prevVolume": 2222200,
    "averageVolume": 2158566.6666666665,
    "volumeChange": -19.93,
    "volumeVsAvg": -17.57,
    "recentVolumes": [
      1454200,
      1515500,
      1829100,
      2222200,
      1779400
    ],
    "marketCap": 18622636032,
    "fiftyTwoWeekHigh": 73.69,
    "fiftyTwoWeekLow": 39.15,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Wall Street Bulls Look Optimistic About Nutanix (NTNX): Should You Buy?",
        "publisher": "Zacks",
        "timestamp": "2024-11-15 06:30:12",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/wall-street-bulls-look-optimistic-143012832.html"
      },
      {
        "title": "Here's Why Nutanix (NTNX) Fell More Than Broader Market",
        "publisher": "Zacks",
        "timestamp": "2024-11-14 14:45:07",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/heres-why-nutanix-ntnx-fell-224507735.html"
      },
      {
        "title": "Nutanix Catalysts Include HCI Growth, VMware Market Share Shift, And AI Demand: Analyst",
        "publisher": "Benzinga",
        "timestamp": "2024-11-13 11:12:55",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/nutanix-catalysts-hci-growth-vmware-191255204.html"
      },
      {
        "title": "Oppenheimer initiates coverage of these 5 storage & infrastructure stocks",
        "publisher": "Investing.com",
        "timestamp": "2024-11-13 09:30:32",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/oppenheimer-initiates-coverage-5-storage-173032188.html"
      },
      {
        "title": "Oppenheimer Initiates Coverage on Nutanix With Outperform Rating, $80 Price Target",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-13 05:30:53",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/oppenheimer-initiates-coverage-nutanix-outperform-133053326.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "INAB",
    "timestamp": "2024-11-17 14:45:56",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 0.34,
    "priceChange": -0.21,
    "openPrice": 0.34,
    "prevClose": 0.34,
    "dayHigh": 0.35,
    "dayLow": 0.31,
    "volume": 534700,
    "prevVolume": 456300,
    "averageVolume": 826205.5555555555,
    "volumeChange": 17.18,
    "volumeVsAvg": -35.28,
    "recentVolumes": [
      198200,
      449200,
      718400,
      456300,
      534700
    ],
    "marketCap": 24303650,
    "fiftyTwoWeekHigh": 2.48,
    "fiftyTwoWeekLow": 0.22,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "INAB: Upcoming Presentations at SNO & ASH",
        "publisher": "Zacks Small Cap Research",
        "timestamp": "2024-11-14 07:14:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/inab-upcoming-presentations-sno-ash-151400737.html"
      },
      {
        "title": "IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-12 13:26:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/in8bio-reports-third-quarter-2024-212600819.html"
      },
      {
        "title": "IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-12 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/in8bio-announces-plenary-oral-presentation-120000805.html"
      },
      {
        "title": "IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-05 06:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/in8bio-announces-upcoming-presentation-2024-140000720.html"
      },
      {
        "title": "INAB: Restructuring Narrows Focus to AML",
        "publisher": "Zacks Small Cap Research",
        "timestamp": "2024-10-02 04:18:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/inab-restructuring-narrows-focus-aml-111800608.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "MNPR",
    "timestamp": "2024-11-17 14:45:57",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 18.0,
    "priceChange": -1.23,
    "openPrice": 17.21,
    "prevClose": 18.23,
    "dayHigh": 19.0,
    "dayLow": 17.09,
    "volume": 129000,
    "prevVolume": 116000,
    "averageVolume": 913932.0,
    "volumeChange": 11.21,
    "volumeVsAvg": -85.89,
    "recentVolumes": [
      103200,
      143300,
      153600,
      116000,
      129000
    ],
    "marketCap": 95475400,
    "fiftyTwoWeekHigh": 38.5,
    "fiftyTwoWeekLow": 1.37,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Monopar Therapeutics Reports Third Quarter 2024\u00a0Financial Results and Recent Developments",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-08 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/monopar-therapeutics-reports-third-quarter-130000859.html"
      },
      {
        "title": "Monopar Therapeutics Closes $19.2 Million Common Stock Offering",
        "publisher": "MT Newswires",
        "timestamp": "2024-10-30 12:06:16",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/monopar-therapeutics-closes-19-2-190616413.html"
      },
      {
        "title": "Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-30 10:42:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/monopar-therapeutics-inc-announces-closing-174200338.html"
      },
      {
        "title": "Monopar Therapeutics Prices Best Efforts Public Offering at $16.25 per Share",
        "publisher": "MT Newswires",
        "timestamp": "2024-10-29 02:22:52",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/monopar-therapeutics-prices-best-efforts-092252621.html"
      },
      {
        "title": "Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-28 18:15:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/monopar-therapeutics-inc-announces-pricing-011500549.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "APVO",
    "timestamp": "2024-11-17 14:45:57",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 0.21,
    "priceChange": -12.45,
    "openPrice": 0.24,
    "prevClose": 0.24,
    "dayHigh": 0.24,
    "dayLow": 0.21,
    "volume": 751300,
    "prevVolume": 612600,
    "averageVolume": 8586395.555555556,
    "volumeChange": 22.64,
    "volumeVsAvg": -91.25,
    "recentVolumes": [
      3926300,
      1037400,
      1459600,
      612600,
      751300
    ],
    "marketCap": 3906053,
    "fiftyTwoWeekHigh": 10.8,
    "fiftyTwoWeekLow": 0.14,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial",
        "publisher": "ACCESSWIRE",
        "timestamp": "2024-11-11 05:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/first-class-bispecific-antibody-alg-130500184.html"
      },
      {
        "title": "Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update",
        "publisher": "ACCESSWIRE",
        "timestamp": "2024-11-07 05:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/aptevo-therapeutics-reports-3q-2024-130500926.html"
      },
      {
        "title": "Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024",
        "publisher": "ACCESSWIRE",
        "timestamp": "2024-10-29 05:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/aptevo-therapeutics-alligator-bioscience-present-120500855.html"
      },
      {
        "title": "Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules",
        "publisher": "ACCESSWIRE",
        "timestamp": "2024-09-18 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/aptevo-therapeutics-announces-closing-3-200500591.html"
      },
      {
        "title": "Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules",
        "publisher": "ACCESSWIRE",
        "timestamp": "2024-09-16 17:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/aptevo-therapeutics-announces-3-0-000500375.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "HRMY",
    "timestamp": "2024-11-17 14:45:58",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 33.21,
    "priceChange": 0.64,
    "openPrice": 32.95,
    "prevClose": 33.0,
    "dayHigh": 33.51,
    "dayLow": 32.55,
    "volume": 598300,
    "prevVolume": 490900,
    "averageVolume": 616341.1111111111,
    "volumeChange": 21.88,
    "volumeVsAvg": -2.93,
    "recentVolumes": [
      533500,
      909100,
      538200,
      490900,
      598300
    ],
    "marketCap": 1894294656,
    "fiftyTwoWeekHigh": 41.61,
    "fiftyTwoWeekLow": 27.11,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "There May Be Some Bright Spots In Harmony Biosciences Holdings' (NASDAQ:HRMY) Earnings",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-05 02:53:22",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/may-bright-spots-harmony-biosciences-105322581.html"
      },
      {
        "title": "Earnings Beat: Harmony Biosciences Holdings, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-01 08:14:57",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/earnings-beat-harmony-biosciences-holdings-151457942.html"
      },
      {
        "title": "Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?",
        "publisher": "Zacks",
        "timestamp": "2024-11-01 06:40:15",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/investors-undervaluing-harmony-biosciences-hrmy-134015831.html"
      },
      {
        "title": "HRMY vs. REGN: Which Stock Is the Better Value Option?",
        "publisher": "Zacks",
        "timestamp": "2024-10-31 08:40:08",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/hrmy-vs-regn-stock-better-154008123.html"
      },
      {
        "title": "Harmony Biosciences Holdings Third Quarter 2024 Earnings: Beats Expectations",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-10-31 05:28:49",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/harmony-biosciences-holdings-third-quarter-122849315.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "BHC",
    "timestamp": "2024-11-17 14:45:58",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "price": 8.48,
    "priceChange": -3.14,
    "openPrice": 8.72,
    "prevClose": 8.76,
    "dayHigh": 8.73,
    "dayLow": 8.47,
    "volume": 1027600,
    "prevVolume": 859400,
    "averageVolume": 3067595.5555555555,
    "volumeChange": 19.57,
    "volumeVsAvg": -66.5,
    "recentVolumes": [
      1749800,
      1631200,
      1403200,
      859400,
      1027600
    ],
    "marketCap": 3133402112,
    "fiftyTwoWeekHigh": 11.46,
    "fiftyTwoWeekLow": 3.96,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Are Medical Stocks Lagging  Bausch Health (BHC) This Year?",
        "publisher": "Zacks",
        "timestamp": "2024-11-06 06:40:10",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/medical-stocks-lagging-bausch-health-144010030.html"
      },
      {
        "title": "Why Bausch Health (BHC) is a Top Momentum Stock for the Long-Term",
        "publisher": "Zacks",
        "timestamp": "2024-11-04 06:50:10",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/why-bausch-health-bhc-top-145010506.html"
      },
      {
        "title": "RBC on Bausch Health's Q3",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-01 11:33:28",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/rbc-bausch-health-apos-q3-183328028.html"
      },
      {
        "title": "Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boosts Sales",
        "publisher": "Zacks",
        "timestamp": "2024-11-01 10:42:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/bausch-health-q3-earnings-revenues-174200087.html"
      },
      {
        "title": "RBC Lifts Price Target on Bausch Health to $11 From $10, Keeps Sector Perform Rating",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-01 04:53:18",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/rbc-lifts-price-target-bausch-115318216.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "BCRX",
    "timestamp": "2024-11-17 14:45:59",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 7.03,
    "priceChange": -5.64,
    "openPrice": 7.5,
    "prevClose": 7.45,
    "dayHigh": 7.52,
    "dayLow": 6.93,
    "volume": 2831500,
    "prevVolume": 1876400,
    "averageVolume": 2168710.0,
    "volumeChange": 50.9,
    "volumeVsAvg": 30.56,
    "recentVolumes": [
      1825800,
      1695700,
      1308100,
      1876400,
      2831500
    ],
    "marketCap": 1456145024,
    "fiftyTwoWeekHigh": 8.88,
    "fiftyTwoWeekLow": 4.03,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "BioCryst to Present at Upcoming Investor Conferences",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-06 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/biocryst-present-upcoming-investor-conferences-120000849.html"
      },
      {
        "title": "BioCryst Announces Strong Q3 2024 Revenue Growth",
        "publisher": "TipRanks",
        "timestamp": "2024-11-05 04:29:50",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/biocryst-announces-strong-q3-2024-122950057.html"
      },
      {
        "title": "BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-05 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/biocryst-reports-inducement-grants-under-120000402.html"
      },
      {
        "title": "BioCryst Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-05 02:13:42",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/biocryst-pharmaceuticals-third-quarter-2024-101342477.html"
      },
      {
        "title": "Q3 2024 BioCryst Pharmaceuticals Inc Earnings Call",
        "publisher": "Thomson Reuters StreetEvents",
        "timestamp": "2024-11-04 23:32:44",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/q3-2024-biocryst-pharmaceuticals-inc-073244042.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "GRTX",
    "timestamp": "2024-11-17 14:46:00",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 0.04,
    "priceChange": -7.78,
    "openPrice": 0.04,
    "prevClose": 0.05,
    "dayHigh": 0.04,
    "dayLow": 0.04,
    "volume": 19400,
    "prevVolume": 112900,
    "averageVolume": 253580.0,
    "volumeChange": -82.82,
    "volumeVsAvg": -92.35,
    "recentVolumes": [
      56100,
      4400,
      32800,
      112900,
      19400
    ],
    "marketCap": 2338864,
    "fiftyTwoWeekHigh": 0.29,
    "fiftyTwoWeekLow": 0.04,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": false
    }
  },
  {
    "symbol": "AXSM",
    "timestamp": "2024-11-17 14:46:00",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 93.18,
    "priceChange": -4.3,
    "openPrice": 97.81,
    "prevClose": 97.37,
    "dayHigh": 97.81,
    "dayLow": 92.52,
    "volume": 770600,
    "prevVolume": 765800,
    "averageVolume": 479595.55555555556,
    "volumeChange": 0.63,
    "volumeVsAvg": 60.68,
    "recentVolumes": [
      757100,
      1564800,
      1225300,
      765800,
      770600
    ],
    "marketCap": 4515241472,
    "fiftyTwoWeekHigh": 105.0,
    "fiftyTwoWeekLow": 58.61,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up",
        "publisher": "Zacks",
        "timestamp": "2024-11-13 08:08:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/axsomes-q3-earnings-beat-auvelity-160800147.html"
      },
      {
        "title": "Q3 2024 Axsome Therapeutics Inc Earnings Call",
        "publisher": "Thomson Reuters StreetEvents",
        "timestamp": "2024-11-13 00:27:26",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/q3-2024-axsome-therapeutics-inc-082726309.html"
      },
      {
        "title": "Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript",
        "publisher": "Motley Fool",
        "timestamp": "2024-11-12 12:15:17",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/eb0de267-b732-311a-9347-d4e13282f53c/axsome-therapeutics-%28axsm%29-q3.html"
      },
      {
        "title": "Axsome Hits 52-Week High After Surging Nearly 5%--FDA Milestones Could Fuel Even Bigger Gains",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-12 09:42:42",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/axsome-hits-52-week-high-174242780.html"
      },
      {
        "title": "Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-12 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/axsome-therapeutics-reports-third-quarter-120000482.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "SMMT",
    "timestamp": "2024-11-17 14:46:01",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 18.31,
    "priceChange": -5.86,
    "openPrice": 19.45,
    "prevClose": 19.45,
    "dayHigh": 19.45,
    "dayLow": 18.23,
    "volume": 2144200,
    "prevVolume": 1875700,
    "averageVolume": 4214707.777777778,
    "volumeChange": 14.31,
    "volumeVsAvg": -49.13,
    "recentVolumes": [
      2163800,
      1876200,
      1903900,
      1875700,
      2144200
    ],
    "marketCap": 13502672896,
    "fiftyTwoWeekHigh": 33.89,
    "fiftyTwoWeekLow": 1.89,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics",
        "publisher": "Investor's Business Daily",
        "timestamp": "2024-11-14 13:54:56",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/33caf774-3385-38de-951c-888517a54dba/merck-spends-up-to-%243.3.html"
      },
      {
        "title": "TipRanks\u2019 \u2018Perfect 10\u2019 Picks: 2 Top-Scoring Stocks for the Rest of 2024",
        "publisher": "TipRanks",
        "timestamp": "2024-11-10 15:26:26",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/tipranks-perfect-10-picks-2-232626426.html"
      },
      {
        "title": "2 Hot Biopharma Stocks to Buy and Hold for 5 Years",
        "publisher": "Motley Fool",
        "timestamp": "2024-11-08 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/8d2d6389-c522-30f9-9113-1e2ccffb0f14/2-hot-biopharma-stocks-to-buy.html"
      },
      {
        "title": "Why Summit Therapeutics Stock Was a Winner Today",
        "publisher": "Motley Fool",
        "timestamp": "2024-11-04 15:56:35",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/166ef84d-21e6-35c6-8714-d4bb35f3d276/why-summit-therapeutics-stock.html"
      },
      {
        "title": "Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo",
        "publisher": "Benzinga",
        "timestamp": "2024-11-04 11:14:17",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/summit-therapeutics-unique-investment-oncology-191417986.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "SAGE",
    "timestamp": "2024-11-17 14:46:01",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 5.1,
    "priceChange": -5.03,
    "openPrice": 5.44,
    "prevClose": 5.37,
    "dayHigh": 5.44,
    "dayLow": 5.03,
    "volume": 1175700,
    "prevVolume": 892300,
    "averageVolume": 746041.1111111111,
    "volumeChange": 31.76,
    "volumeVsAvg": 57.59,
    "recentVolumes": [
      518500,
      563700,
      500600,
      892300,
      1175700
    ],
    "marketCap": 311983840,
    "fiftyTwoWeekHigh": 28.26,
    "fiftyTwoWeekLow": 5.03,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Sage Therapeutics price target lowered to $26 from $52 at Piper Sandler",
        "publisher": "TipRanks",
        "timestamp": "2024-10-31 04:39:41",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/sage-therapeutics-price-target-lowered-113941225.html"
      },
      {
        "title": "SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down",
        "publisher": "Zacks",
        "timestamp": "2024-10-30 06:40:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/sages-q3-loss-wider-expected-134000040.html"
      },
      {
        "title": "Biogen, Sage admit a defeat in major depression",
        "publisher": "BioPharma Dive",
        "timestamp": "2024-10-30 04:38:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/a0a8746d-2460-3178-8d34-6af92c110c88/biogen%2C-sage-admit-a-defeat.html"
      },
      {
        "title": "Sage Therapeutics Inc (SAGE) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-10-30 00:13:07",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/sage-therapeutics-inc-sage-q3-071307898.html"
      },
      {
        "title": "Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates",
        "publisher": "Zacks",
        "timestamp": "2024-10-29 14:20:10",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/sage-therapeutics-inc-sage-reports-212010068.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 5,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "MYNZ",
    "timestamp": "2024-11-17 14:46:02",
    "sector": "Healthcare",
    "industry": "Diagnostics & Research",
    "price": 0.24,
    "priceChange": -4.6,
    "openPrice": 0.25,
    "prevClose": 0.25,
    "dayHigh": 0.25,
    "dayLow": 0.23,
    "volume": 2659100,
    "prevVolume": 4797100,
    "averageVolume": 2583664.4444444445,
    "volumeChange": -44.57,
    "volumeVsAvg": 2.92,
    "recentVolumes": [
      2513500,
      51333200,
      6902900,
      4797100,
      2659100
    ],
    "marketCap": 15286587,
    "fiftyTwoWeekHigh": 1.79,
    "fiftyTwoWeekLow": 0.18,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "The Oncology Bet Is Already Paying Off For Pfizer",
        "publisher": "Benzinga",
        "timestamp": "2024-11-13 16:23:15",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/oncology-bet-already-paying-off-002315025.html"
      },
      {
        "title": "Mainz Biomed, Thermo Fisher Partner to Develop Colorectal Cancer Screening Test",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-12 06:54:56",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mainz-biomed-thermo-fisher-partner-145456741.html"
      },
      {
        "title": "Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-12 06:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mainz-biomed-thermo-fisher-scientific-140000609.html"
      },
      {
        "title": "Mainz Biomed restructured operations, implemented cost reductions",
        "publisher": "TipRanks",
        "timestamp": "2024-10-22 05:10:53",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mainz-biomed-restructured-operations-implemented-121053683.html"
      },
      {
        "title": "Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-21 05:01:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mainz-biomed-reports-mid-2024-120100378.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "GMAB",
    "timestamp": "2024-11-17 14:46:03",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 20.6,
    "priceChange": -2.74,
    "openPrice": 20.99,
    "prevClose": 21.18,
    "dayHigh": 21.01,
    "dayLow": 20.5,
    "volume": 1310600,
    "prevVolume": 2462400,
    "averageVolume": 915753.3333333334,
    "volumeChange": -46.78,
    "volumeVsAvg": 43.12,
    "recentVolumes": [
      1654100,
      1373300,
      2583600,
      2462400,
      1310600
    ],
    "marketCap": 13654197248,
    "fiftyTwoWeekHigh": 32.88,
    "fiftyTwoWeekLow": 20.5,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Genmab A/S (GMAB): Among 12 High Growth Large Cap Stocks to Buy Now",
        "publisher": "Insider Monkey",
        "timestamp": "2024-11-15 09:22:31",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/genmab-gmab-among-12-high-172231705.html"
      },
      {
        "title": "High Growth Tech Stocks To Watch In November 2024",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-07 23:03:30",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/high-growth-tech-stocks-watch-070330387.html"
      },
      {
        "title": "Genmab AS (GMAB) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Pipeline ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-06 23:20:09",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/genmab-gmab-q3-2024-earnings-072009368.html"
      },
      {
        "title": "Genmab Shares Fall After Reporting Q3 Results",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-06 10:02:21",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/genmab-shares-fall-reporting-q3-180221423.html"
      },
      {
        "title": "Genmab Announces Financial Results for the First Nine Months of 2024",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-06 08:02:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/genmab-announces-financial-results-first-160200818.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "LUMO",
    "timestamp": "2024-11-17 14:46:03",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 4.33,
    "priceChange": 0.0,
    "openPrice": 4.34,
    "prevClose": 4.33,
    "dayHigh": 4.39,
    "dayLow": 4.3,
    "volume": 101600,
    "prevVolume": 22700,
    "averageVolume": 86425.55555555556,
    "volumeChange": 347.58,
    "volumeVsAvg": 17.56,
    "recentVolumes": [
      166800,
      141300,
      96600,
      22700,
      101600
    ],
    "marketCap": 37448524,
    "fiftyTwoWeekHigh": 4.58,
    "fiftyTwoWeekLow": 1.37,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62\u207f\u1d48 Annual ESPE Meeting 2024",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-30 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/lumos-pharma-announces-two-abstracts-200500186.html"
      },
      {
        "title": "Discover Smart Share Global Among 2 Other Prominent US Penny Stocks",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-10-25 13:04:47",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/discover-smart-share-global-among-200447368.html"
      },
      {
        "title": "Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR)",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-23 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/lumos-pharma-enters-definitive-merger-120000720.html"
      },
      {
        "title": "Lumos Pharma Inc (LUMO) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Prudence",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-10-09 12:51:41",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/lumos-pharma-inc-lumo-q2-195141149.html"
      },
      {
        "title": "Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-09-25 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/lumos-pharma-announces-abstract-accepted-200500588.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "NEO",
    "timestamp": "2024-11-17 14:46:04",
    "sector": "Healthcare",
    "industry": "Diagnostics & Research",
    "price": 15.03,
    "priceChange": -4.81,
    "openPrice": 16.0,
    "prevClose": 15.79,
    "dayHigh": 16.0,
    "dayLow": 15.01,
    "volume": 582400,
    "prevVolume": 681100,
    "averageVolume": 792462.2222222222,
    "volumeChange": -14.49,
    "volumeVsAvg": -26.51,
    "recentVolumes": [
      975700,
      706500,
      676500,
      681100,
      582400
    ],
    "marketCap": 1930549376,
    "fiftyTwoWeekHigh": 21.22,
    "fiftyTwoWeekLow": 12.77,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Felicia Williams Joins NeoGenomics Board of Directors",
        "publisher": "Business Wire",
        "timestamp": "2024-11-14 05:10:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/felicia-williams-joins-neogenomics-board-131000061.html"
      },
      {
        "title": "NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference",
        "publisher": "Business Wire",
        "timestamp": "2024-11-08 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/neogenomics-participate-piper-sandler-36th-120000236.html"
      },
      {
        "title": "NeoGenomics (NEO) Upgraded to Strong Buy: Here's What You Should Know",
        "publisher": "Zacks",
        "timestamp": "2024-11-06 09:00:11",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/neogenomics-neo-upgraded-strong-buy-170011070.html"
      },
      {
        "title": "NeoGenomics Third Quarter 2024 Earnings: EPS Beats Expectations",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-06 02:59:08",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/neogenomics-third-quarter-2024-earnings-105908936.html"
      },
      {
        "title": "Q3 2024 Neogenomics Inc Earnings Call",
        "publisher": "Thomson Reuters StreetEvents",
        "timestamp": "2024-11-05 23:24:03",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/q3-2024-neogenomics-inc-earnings-072403182.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ARCT",
    "timestamp": "2024-11-17 14:46:04",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 16.01,
    "priceChange": -12.68,
    "openPrice": 18.0,
    "prevClose": 18.34,
    "dayHigh": 18.0,
    "dayLow": 14.93,
    "volume": 1208600,
    "prevVolume": 403000,
    "averageVolume": 383534.44444444444,
    "volumeChange": 199.9,
    "volumeVsAvg": 215.12,
    "recentVolumes": [
      672300,
      534700,
      286100,
      403000,
      1208600
    ],
    "marketCap": 433940160,
    "fiftyTwoWeekHigh": 45.0,
    "fiftyTwoWeekLow": 14.93,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Meiji Seika Pharma Announces Investment in ARCALIS, Inc.",
        "publisher": "Business Wire",
        "timestamp": "2024-11-13 22:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/meiji-seika-pharma-announces-investment-060000101.html"
      },
      {
        "title": "Arcturus Therapeutics Gets FDA Greenlight for H5N1 Pandemic Flu Vaccine Trial",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-11 14:19:16",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/arcturus-therapeutics-gets-fda-greenlight-221916482.html"
      },
      {
        "title": "Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial",
        "publisher": "Business Wire",
        "timestamp": "2024-11-11 13:01:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/arcturus-therapeutics-receives-clearance-fda-210100627.html"
      },
      {
        "title": "Arcturus Therapeutics Holdings Third Quarter 2024 Earnings: Beats Expectations",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-09 06:25:32",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/arcturus-therapeutics-holdings-third-quarter-142532243.html"
      },
      {
        "title": "Q3 2024 Arcturus Therapeutics Holdings Inc Earnings Call",
        "publisher": "Thomson Reuters StreetEvents",
        "timestamp": "2024-11-08 09:15:05",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/q3-2024-arcturus-therapeutics-holdings-171505971.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 5,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "TEVA",
    "timestamp": "2024-11-17 14:46:05",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "price": 16.43,
    "priceChange": -1.88,
    "openPrice": 16.22,
    "prevClose": 16.75,
    "dayHigh": 16.63,
    "dayLow": 16.16,
    "volume": 8734100,
    "prevVolume": 9547600,
    "averageVolume": 7514258.888888889,
    "volumeChange": -8.52,
    "volumeVsAvg": 16.23,
    "recentVolumes": [
      7463500,
      7402800,
      4649600,
      9547600,
      8734100
    ],
    "marketCap": 19009017856,
    "fiftyTwoWeekHigh": 19.31,
    "fiftyTwoWeekLow": 9.04,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory",
        "publisher": "Insider Monkey",
        "timestamp": "2024-11-15 06:09:31",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/teva-pharmaceutical-industries-limited-teva-140931397.html"
      },
      {
        "title": "Teva to Present at the Jefferies London Healthcare Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-08 13:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/teva-present-jefferies-london-healthcare-213000389.html"
      },
      {
        "title": "Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?",
        "publisher": "Zacks",
        "timestamp": "2024-11-08 06:40:16",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/investors-undervaluing-teva-pharmaceutical-industries-144016602.html"
      },
      {
        "title": "Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated",
        "publisher": "Zacks",
        "timestamp": "2024-11-07 07:39:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/amicus-q3-earnings-revenues-beat-153900681.html"
      },
      {
        "title": "TEVA Stock Down 7% Despite Q3 Earnings & Sales Beat, Guidance Increase",
        "publisher": "Zacks",
        "timestamp": "2024-11-07 05:50:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/teva-stock-down-7-despite-135000067.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "VMD",
    "timestamp": "2024-11-17 14:46:06",
    "sector": "Healthcare",
    "industry": "Medical Devices",
    "price": 8.83,
    "priceChange": -2.54,
    "openPrice": 9.13,
    "prevClose": 9.06,
    "dayHigh": 9.13,
    "dayLow": 8.83,
    "volume": 202600,
    "prevVolume": 166500,
    "averageVolume": 150204.44444444444,
    "volumeChange": 21.68,
    "volumeVsAvg": 34.88,
    "recentVolumes": [
      427200,
      217900,
      254500,
      166500,
      202600
    ],
    "marketCap": 344588928,
    "fiftyTwoWeekHigh": 10.44,
    "fiftyTwoWeekLow": 6.21,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Viemed Healthcare Announces Third Quarter 2024 Financial Results",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-06 13:45:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/viemed-healthcare-announces-third-quarter-214500322.html"
      },
      {
        "title": "3 US Growth Stocks With Insider Ownership Up To 31%",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-10-28 04:01:28",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/3-us-growth-stocks-insider-110128615.html"
      },
      {
        "title": "Discovering Three Hidden Gems In The US Market",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-10-23 08:04:03",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/discovering-three-hidden-gems-us-150403127.html"
      },
      {
        "title": "Viemed Healthcare Announces Third Quarter 2024 Earnings Conference Call Details",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-22 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/viemed-healthcare-announces-third-quarter-120000892.html"
      },
      {
        "title": "3 Growth Companies With High Insider Ownership In US Growing Revenues At 20%",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-09-27 04:03:14",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/3-growth-companies-high-insider-110314147.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "VERU",
    "timestamp": "2024-11-17 14:46:06",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 0.58,
    "priceChange": -7.75,
    "openPrice": 0.64,
    "prevClose": 0.63,
    "dayHigh": 0.64,
    "dayLow": 0.58,
    "volume": 1328200,
    "prevVolume": 1128200,
    "averageVolume": 700076.6666666666,
    "volumeChange": 17.73,
    "volumeVsAvg": 89.72,
    "recentVolumes": [
      660000,
      1887900,
      817000,
      1128200,
      1328200
    ],
    "marketCap": 85429704,
    "fiftyTwoWeekHigh": 1.92,
    "fiftyTwoWeekLow": 0.36,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-05 05:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/veru-announces-meta-analysis-body-133000832.html"
      },
      {
        "title": "Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-21 05:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/veru-present-obesityweek-meta-analysis-123000802.html"
      },
      {
        "title": "Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-16 05:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/veru-deliver-keynote-presentation-scientific-123000932.html"
      },
      {
        "title": "Veru Inc (VERU) Q3 2024 Earnings Call Highlights: Strategic Cost Management and Revenue Growth ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-10-09 14:27:59",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/veru-inc-veru-q3-2024-212759580.html"
      },
      {
        "title": "Veru to Present at the 2024 Cantor Global Healthcare Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-09-11 05:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/veru-present-2024-cantor-global-123000549.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": false,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "VRCA",
    "timestamp": "2024-11-17 14:46:07",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 0.84,
    "priceChange": -2.67,
    "openPrice": 0.87,
    "prevClose": 0.86,
    "dayHigh": 0.89,
    "dayLow": 0.79,
    "volume": 277500,
    "prevVolume": 449000,
    "averageVolume": 877454.4444444445,
    "volumeChange": -38.2,
    "volumeVsAvg": -68.37,
    "recentVolumes": [
      1222000,
      631800,
      342200,
      449000,
      277500
    ],
    "marketCap": 38008268,
    "fiftyTwoWeekHigh": 11.41,
    "fiftyTwoWeekLow": 0.7,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-04 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/verrica-pharmaceuticals-reports-third-quarter-210500868.html"
      },
      {
        "title": "Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-24 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/verrica-pharmaceuticals-announces-acceptance-two-110000393.html"
      },
      {
        "title": "Verrica Pharmaceuticals Inc (VRCA) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Rising ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-10-09 15:21:40",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/verrica-pharmaceuticals-inc-vrca-q2-222140818.html"
      },
      {
        "title": "RBC Lowers Price Target on Verrica Pharmaceuticals to $11 From $13, Keeps Outperform, Speculative Risk",
        "publisher": "MT Newswires",
        "timestamp": "2024-10-04 04:39:40",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/rbc-lowers-price-target-verrica-113940759.html"
      },
      {
        "title": "Sector Update: Health Care Stocks Softer Wednesday Afternoon",
        "publisher": "MT Newswires",
        "timestamp": "2024-10-02 10:53:58",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/sector-health-care-stocks-softer-175358747.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "SIGA",
    "timestamp": "2024-11-17 14:46:08",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "price": 5.94,
    "priceChange": -5.71,
    "openPrice": 6.26,
    "prevClose": 6.3,
    "dayHigh": 6.33,
    "dayLow": 5.91,
    "volume": 774200,
    "prevVolume": 605500,
    "averageVolume": 1153528.888888889,
    "volumeChange": 27.86,
    "volumeVsAvg": -32.88,
    "recentVolumes": [
      615900,
      444200,
      520900,
      605500,
      774200
    ],
    "marketCap": 424143936,
    "fiftyTwoWeekHigh": 12.83,
    "fiftyTwoWeekLow": 4.26,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Impressive Earnings May Not Tell The Whole Story For SIGA Technologies (NASDAQ:SIGA)",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-15 02:32:08",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/impressive-earnings-may-not-tell-103208966.html"
      },
      {
        "title": "SIGA Technologies Third Quarter 2024 Earnings: EPS: US$0.019 (vs US$0.006 loss in 3Q 2023)",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-09 04:41:31",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/siga-technologies-third-quarter-2024-124131733.html"
      },
      {
        "title": "SIGA Technologies Inc (SIGA) Q3 2024 Earnings Call Highlights: Strong Procurement Orders and ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-07 23:35:54",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/siga-technologies-inc-siga-q3-073554393.html"
      },
      {
        "title": "SIGA Reports Financial Results for Three and Nine\u00a0Months Ended September 30, 2024",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-07 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/siga-reports-financial-results-three-210500401.html"
      },
      {
        "title": "SIGA to Host Business Update Call on November 7 Following Release of Third-Quarter 2024 Financial Results",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-31 04:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/siga-host-business-call-november-113000668.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "INMD",
    "timestamp": "2024-11-17 14:46:08",
    "sector": "Healthcare",
    "industry": "Medical Devices",
    "price": 18.0,
    "priceChange": -5.26,
    "openPrice": 19.0,
    "prevClose": 19.0,
    "dayHigh": 19.22,
    "dayLow": 18.0,
    "volume": 1379100,
    "prevVolume": 910600,
    "averageVolume": 1154660.0,
    "volumeChange": 51.45,
    "volumeVsAvg": 19.44,
    "recentVolumes": [
      929200,
      906000,
      887000,
      910600,
      1379100
    ],
    "marketCap": 1373246336,
    "fiftyTwoWeekHigh": 26.8,
    "fiftyTwoWeekLow": 14.87,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "InMode to Present at Upcoming Investor Conferences",
        "publisher": "PR Newswire",
        "timestamp": "2024-11-06 05:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/inmode-present-upcoming-investor-conferences-133000805.html"
      },
      {
        "title": "We Think You Can Look Beyond InMode's (NASDAQ:INMD) Lackluster Earnings",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-06 03:35:07",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/think-look-beyond-inmodes-nasdaq-113507789.html"
      },
      {
        "title": "UBS Adjusts Price Target on InMode to $19 From $17, Maintains Neutral Rating",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-01 06:59:29",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ubs-adjusts-price-target-inmode-135929729.html"
      },
      {
        "title": "InMode Third Quarter 2024 Earnings: Beats Expectations",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-01 06:09:44",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/inmode-third-quarter-2024-earnings-130944919.html"
      },
      {
        "title": "InMode Sees Revenue Growth Amidst Challenges in Q3 2024",
        "publisher": "TipRanks",
        "timestamp": "2024-10-31 04:29:43",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/inmode-sees-revenue-growth-amidst-112943614.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "EXEL",
    "timestamp": "2024-11-17 14:46:09",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 34.45,
    "priceChange": -1.71,
    "openPrice": 34.98,
    "prevClose": 35.05,
    "dayHigh": 35.13,
    "dayLow": 34.07,
    "volume": 2867800,
    "prevVolume": 2980600,
    "averageVolume": 2040640.0,
    "volumeChange": -3.78,
    "volumeVsAvg": 40.53,
    "recentVolumes": [
      1914600,
      1666900,
      2011000,
      2980600,
      2867800
    ],
    "marketCap": 9838196736,
    "fiftyTwoWeekHigh": 36.6,
    "fiftyTwoWeekLow": 19.2,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?",
        "publisher": "Zacks",
        "timestamp": "2024-11-12 06:15:11",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/adma-biologics-inc-adma-hits-141511648.html"
      },
      {
        "title": "Vericel Stock Sees RS Rating Shoot Higher",
        "publisher": "Investor's Business Daily",
        "timestamp": "2024-11-11 11:06:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/0099c707-e838-3e9f-85a4-657e7cfe7b7a/vericel-stock-sees-rs-rating.html"
      },
      {
        "title": "What Makes Exelixis (EXEL) a Strong Momentum Stock: Buy Now?",
        "publisher": "Zacks",
        "timestamp": "2024-11-11 09:00:11",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/makes-exelixis-exel-strong-momentum-170011791.html"
      },
      {
        "title": "Here's Why Exelixis (EXEL) is a Strong Momentum Stock",
        "publisher": "Zacks",
        "timestamp": "2024-11-11 06:50:10",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/heres-why-exelixis-exel-strong-145010533.html"
      },
      {
        "title": "Exelixis Insider Sold Shares Worth $3,394,510, According to a Recent SEC Filing",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-08 00:28:56",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/exelixis-insider-sold-shares-worth-082856605.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "CPRX",
    "timestamp": "2024-11-17 14:46:09",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 20.59,
    "priceChange": -5.07,
    "openPrice": 21.6,
    "prevClose": 21.69,
    "dayHigh": 21.63,
    "dayLow": 20.44,
    "volume": 1708500,
    "prevVolume": 1226400,
    "averageVolume": 992235.5555555555,
    "volumeChange": 39.31,
    "volumeVsAvg": 72.19,
    "recentVolumes": [
      1930100,
      1314700,
      895100,
      1226400,
      1708500
    ],
    "marketCap": 2457023744,
    "fiftyTwoWeekHigh": 24.27,
    "fiftyTwoWeekLow": 13.0,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock",
        "publisher": "Zacks",
        "timestamp": "2024-11-15 06:45:13",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/heres-why-catalyst-pharmaceutical-cprx-144513991.html"
      },
      {
        "title": "Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-13 05:03:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/catalyst-pharmaceuticals-recognized-among-biospace-130300293.html"
      },
      {
        "title": "Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings May Just Be The Starting Point",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-13 02:48:57",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/catalyst-pharmaceuticals-nasdaq-cprx-earnings-104857709.html"
      },
      {
        "title": "Vericel Stock Sees RS Rating Shoot Higher",
        "publisher": "Investor's Business Daily",
        "timestamp": "2024-11-11 11:06:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/0099c707-e838-3e9f-85a4-657e7cfe7b7a/vericel-stock-sees-rs-rating.html"
      },
      {
        "title": "Catalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-10 15:00:40",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/catalyst-pharmaceuticals-inc-cprx-q3-230040366.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 5,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "HALO",
    "timestamp": "2024-11-17 14:46:10",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 45.64,
    "priceChange": -15.42,
    "openPrice": 48.81,
    "prevClose": 53.96,
    "dayHigh": 49.64,
    "dayLow": 45.62,
    "volume": 7231200,
    "prevVolume": 3219200,
    "averageVolume": 1418456.6666666667,
    "volumeChange": 124.63,
    "volumeVsAvg": 409.79,
    "recentVolumes": [
      1469900,
      1510800,
      830600,
      3219200,
      7231200
    ],
    "marketCap": 5807912960,
    "fiftyTwoWeekHigh": 65.53,
    "fiftyTwoWeekLow": 33.15,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion",
        "publisher": "Benzinga",
        "timestamp": "2024-11-15 09:56:11",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/large-pharma-partner-halozyme-therapeutics-175620387.html"
      },
      {
        "title": "Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock",
        "publisher": "Zacks",
        "timestamp": "2024-11-15 06:50:10",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/heres-why-halozyme-therapeutics-halo-145010502.html"
      },
      {
        "title": "Halozyme Submits $2.11 Billion Acquisition Offer For Evotec",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-15 03:31:05",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/halozyme-submits-2-11-billion-113105688.html"
      },
      {
        "title": "Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid",
        "publisher": "Investing.com",
        "timestamp": "2024-11-15 02:11:45",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/evotec-shares-surge-20-halozymes-101145566.html"
      },
      {
        "title": "Halozyme bids for Evotec; BeiGene gets a new name",
        "publisher": "BioPharma Dive",
        "timestamp": "2024-11-15 02:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/752a4a0f-351f-3798-b6af-0c4debb3b03a/halozyme-bids-for-evotec%3B.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 5,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "NVOS",
    "timestamp": "2024-11-17 14:46:11",
    "sector": "Healthcare",
    "industry": "Medical Care Facilities",
    "price": 0.04,
    "priceChange": -7.44,
    "openPrice": 0.05,
    "prevClose": 0.04,
    "dayHigh": 0.05,
    "dayLow": 0.04,
    "volume": 165600,
    "prevVolume": 107700,
    "averageVolume": 871963.3333333334,
    "volumeChange": 53.76,
    "volumeVsAvg": -81.01,
    "recentVolumes": [
      599100,
      560300,
      654400,
      107700,
      165600
    ],
    "marketCap": 687867,
    "fiftyTwoWeekHigh": 1.61,
    "fiftyTwoWeekLow": 0.03,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": false
    }
  },
  {
    "symbol": "ATAI",
    "timestamp": "2024-11-17 14:46:11",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 1.62,
    "priceChange": 17.88,
    "openPrice": 1.5,
    "prevClose": 1.37,
    "dayHigh": 1.65,
    "dayLow": 1.43,
    "volume": 6092400,
    "prevVolume": 1860800,
    "averageVolume": 851420.0,
    "volumeChange": 227.41,
    "volumeVsAvg": 615.56,
    "recentVolumes": [
      2882200,
      2997600,
      2465000,
      1860800,
      6092400
    ],
    "marketCap": 270156416,
    "fiftyTwoWeekHigh": 2.85,
    "fiftyTwoWeekLow": 1.02,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-13 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/atai-life-sciences-reports-third-130000969.html"
      },
      {
        "title": "Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-11 04:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/altimmune-appoints-life-sciences-industry-123000512.html"
      },
      {
        "title": "374Water And 2 Other Promising US Penny Stocks To Watch",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-10-21 12:07:55",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/374water-2-other-promising-us-190755981.html"
      },
      {
        "title": "atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-15 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/atai-life-sciences-participate-2024-120000550.html"
      },
      {
        "title": "atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-09-04 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/atai-life-sciences-participate-h-110000317.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 5,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "BNGO",
    "timestamp": "2024-11-17 14:46:12",
    "sector": "Healthcare",
    "industry": "Medical Instruments & Supplies",
    "price": 0.25,
    "priceChange": -5.31,
    "openPrice": 0.25,
    "prevClose": 0.26,
    "dayHigh": 0.25,
    "dayLow": 0.24,
    "volume": 2829700,
    "prevVolume": 5728500,
    "averageVolume": 2097257.777777778,
    "volumeChange": -50.6,
    "volumeVsAvg": 34.92,
    "recentVolumes": [
      3081700,
      3665600,
      5317500,
      5728500,
      2829700
    ],
    "marketCap": 23595624,
    "fiftyTwoWeekHigh": 2.27,
    "fiftyTwoWeekLow": 0.24,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Bionano Genomics Inc (BNGO) Q3 2024 Earnings Call Highlights: Strategic Shifts Amid Revenue ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-13 23:15:29",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/bionano-genomics-inc-bngo-q3-071529861.html"
      },
      {
        "title": "Bionano Genomics (BNGO) Q3 2024 Earnings Call Transcript",
        "publisher": "Motley Fool",
        "timestamp": "2024-11-13 17:45:20",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/3f20a8d6-c750-3823-8df0-91c0ecc1662d/bionano-genomics-%28bngo%29-q3.html"
      },
      {
        "title": "Bionano Reports Third Quarter 2024 Results and Highlights Recent Business Progress",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-13 13:01:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/bionano-reports-third-quarter-2024-210100976.html"
      },
      {
        "title": "Bionano to Report Third Quarter 2024 Financial Results and Host a Conference Call and Webcast on November 13, 2024",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-07 13:01:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/bionano-report-third-quarter-2024-210100226.html"
      },
      {
        "title": "Bionano Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-31 13:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/bionano-announces-closing-3-million-203000246.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ENOV",
    "timestamp": "2024-11-17 14:46:13",
    "sector": "Industrials",
    "industry": "Specialty Industrial Machinery",
    "price": 46.36,
    "priceChange": 1.73,
    "openPrice": 45.66,
    "prevClose": 45.57,
    "dayHigh": 46.61,
    "dayLow": 45.31,
    "volume": 467600,
    "prevVolume": 574100,
    "averageVolume": 676320.0,
    "volumeChange": -18.55,
    "volumeVsAvg": -30.86,
    "recentVolumes": [
      526700,
      529100,
      447400,
      574100,
      467600
    ],
    "marketCap": 2591505664,
    "fiftyTwoWeekHigh": 65.03,
    "fiftyTwoWeekLow": 38.27,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Enovis (ENOV) Upgraded to Buy: Here's Why",
        "publisher": "Zacks",
        "timestamp": "2024-11-08 09:00:11",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/enovis-enov-upgraded-buy-heres-170011134.html"
      },
      {
        "title": "Wall Street Analysts Predict a 38.95% Upside in Enovis (ENOV): Here's  What You Should Know",
        "publisher": "Zacks",
        "timestamp": "2024-11-08 06:55:06",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/wall-street-analysts-predict-38-145506576.html"
      },
      {
        "title": "Enovis Corp (ENOV) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-06 23:10:01",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/enovis-corp-enov-q3-2024-071001297.html"
      },
      {
        "title": "Q3 2024 Enovis Corp Earnings Call",
        "publisher": "Thomson Reuters StreetEvents",
        "timestamp": "2024-11-06 21:58:50",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/q3-2024-enovis-corp-earnings-055850110.html"
      },
      {
        "title": "Enovis (ENOV) Q3 Earnings and Revenues Beat Estimates",
        "publisher": "Zacks",
        "timestamp": "2024-11-06 04:15:04",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/enovis-enov-q3-earnings-revenues-121504015.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "BIIB",
    "timestamp": "2024-11-17 14:46:13",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "price": 159.95,
    "priceChange": -3.0,
    "openPrice": 165.46,
    "prevClose": 164.89,
    "dayHigh": 166.34,
    "dayLow": 159.6,
    "volume": 1916700,
    "prevVolume": 3210600,
    "averageVolume": 1223538.888888889,
    "volumeChange": -40.3,
    "volumeVsAvg": 56.65,
    "recentVolumes": [
      1458100,
      1406300,
      1394700,
      3210600,
      1916700
    ],
    "marketCap": 23313584128,
    "fiftyTwoWeekHigh": 268.3,
    "fiftyTwoWeekLow": 159.6,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Baird Raises Biogen Price Target to $300 From $294, Maintains Outperform Rating",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-15 06:38:55",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/baird-raises-biogen-price-target-143855242.html"
      },
      {
        "title": "Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe",
        "publisher": "Zacks",
        "timestamp": "2024-11-15 06:04:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/biogen-partner-eisai-gets-positive-140400531.html"
      },
      {
        "title": "European committee takes a second look at Alzheimer's drug and now says it should be approved",
        "publisher": "Associated Press Finance",
        "timestamp": "2024-11-14 11:20:30",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/european-committee-takes-second-look-192030487.html"
      },
      {
        "title": "5 Healthcare Stocks to Buy in a Beaten-Up Sector",
        "publisher": "Barrons.com",
        "timestamp": "2024-11-14 10:53:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/88ea7e23-152a-3d8a-b4b7-3145bd69f84b/5-healthcare-stocks-to-buy-in.html"
      },
      {
        "title": "Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease",
        "publisher": "PR Newswire",
        "timestamp": "2024-11-14 10:29:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/eisai-receives-positive-opinion-chmp-182900087.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "MIST",
    "timestamp": "2024-11-17 14:46:14",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 1.71,
    "priceChange": -5.52,
    "openPrice": 1.81,
    "prevClose": 1.81,
    "dayHigh": 1.81,
    "dayLow": 1.68,
    "volume": 435900,
    "prevVolume": 231000,
    "averageVolume": 206721.11111111112,
    "volumeChange": 88.7,
    "volumeVsAvg": 110.86,
    "recentVolumes": [
      1193300,
      514800,
      665800,
      231000,
      435900
    ],
    "marketCap": 90657432,
    "fiftyTwoWeekHigh": 3.52,
    "fiftyTwoWeekLow": 1.12,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Milestone Pharmaceuticals: Q3 Earnings Snapshot",
        "publisher": "Associated Press Finance",
        "timestamp": "2024-11-12 06:17:33",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/milestone-pharmaceuticals-q3-earnings-snapshot-141733662.html"
      },
      {
        "title": "Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-12 06:03:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/milestone-pharmaceuticals-reports-third-quarter-140300144.html"
      },
      {
        "title": "Individual investors account for 54% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) ownership, while institutions account for 46%",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-10-09 03:56:10",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/individual-investors-account-54-milestone-105610215.html"
      },
      {
        "title": "Milestone Pharmaceuticals to Host Investor KOL Event",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-09-24 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/milestone-pharmaceuticals-host-investor-kol-120000540.html"
      },
      {
        "title": "Milestone Pharmaceuticals' Partner Ji Xing's Phase 3 Trial of Etripamil Meets Primary Endpoint",
        "publisher": "MT Newswires",
        "timestamp": "2024-09-06 06:08:40",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/milestone-pharmaceuticals-apos-partner-ji-130840477.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 5,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ARDX",
    "timestamp": "2024-11-17 14:46:14",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 4.96,
    "priceChange": 5.31,
    "openPrice": 4.84,
    "prevClose": 4.71,
    "dayHigh": 5.06,
    "dayLow": 4.69,
    "volume": 7971400,
    "prevVolume": 6620800,
    "averageVolume": 3829523.3333333335,
    "volumeChange": 20.4,
    "volumeVsAvg": 108.16,
    "recentVolumes": [
      10689400,
      6135900,
      5324700,
      6620800,
      7971400
    ],
    "marketCap": 1177164288,
    "fiftyTwoWeekHigh": 10.13,
    "fiftyTwoWeekLow": 4.06,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Ardelyx Insider Bought Shares Worth $996,598, According to a Recent SEC Filing",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-14 13:38:56",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ardelyx-insider-bought-shares-worth-213856036.html"
      },
      {
        "title": "HC Wainwright Downgrades Ardelyx to Neutral From Buy, Adjusts Price Target to $5.50 From $11.50",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-11 05:17:20",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/hc-wainwright-downgrades-ardelyx-neutral-131720330.html"
      },
      {
        "title": "Ardelyx Shares Fall After Federal Judge Dismisses Lawsuit Against CMS",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-08 10:39:46",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ardelyx-shares-fall-federal-judge-183946799.html"
      },
      {
        "title": "Ardelyx Responds to District Court Decision Granting Motion to Dismiss",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-08 09:31:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ardelyx-responds-district-court-decision-173100798.html"
      },
      {
        "title": "Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-05 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ardelyx-participate-2024-jefferies-london-130000591.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 5,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "CVM",
    "timestamp": "2024-11-17 14:46:15",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 0.56,
    "priceChange": 0.04,
    "openPrice": 0.56,
    "prevClose": 0.56,
    "dayHigh": 0.57,
    "dayLow": 0.56,
    "volume": 385100,
    "prevVolume": 1644300,
    "averageVolume": 1043592.2222222222,
    "volumeChange": -76.58,
    "volumeVsAvg": -63.1,
    "recentVolumes": [
      209600,
      146200,
      701600,
      1644300,
      385100
    ],
    "marketCap": 35744736,
    "fiftyTwoWeekHigh": 3.23,
    "fiftyTwoWeekLow": 0.54,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025",
        "publisher": "Business Wire",
        "timestamp": "2024-11-07 05:15:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/u-fda-cel-sci-agree-131500730.html"
      },
      {
        "title": "FDA\u2019s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI\u2019s Multikine\u00ae to Address Major Treatment Gap for PD-L1 Negative Cancer Patients",
        "publisher": "Business Wire",
        "timestamp": "2024-10-22 06:15:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/fda-oncologic-drugs-advisory-committee-131500707.html"
      },
      {
        "title": "CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine\u00ae in Head and Neck Cancer",
        "publisher": "Business Wire",
        "timestamp": "2024-10-01 03:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/cel-sci-selects-ergomed-cro-100000340.html"
      },
      {
        "title": "CEL-SCI\u2019s Multikine\u00ae Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation",
        "publisher": "Business Wire",
        "timestamp": "2024-09-16 04:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/cel-sci-multikine-increased-5-113000487.html"
      },
      {
        "title": "CEL-SCI to Present New Data for Multikine\u00ae Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress",
        "publisher": "Business Wire",
        "timestamp": "2024-09-10 06:32:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/cel-sci-present-data-multikine-133200511.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ACLS",
    "timestamp": "2024-11-17 14:46:16",
    "sector": "Technology",
    "industry": "Semiconductor Equipment & Materials",
    "price": 73.2,
    "priceChange": -7.17,
    "openPrice": 77.25,
    "prevClose": 78.85,
    "dayHigh": 77.25,
    "dayLow": 73.15,
    "volume": 1003000,
    "prevVolume": 599200,
    "averageVolume": 655651.1111111111,
    "volumeChange": 67.39,
    "volumeVsAvg": 52.98,
    "recentVolumes": [
      752300,
      883600,
      824100,
      599200,
      1003000
    ],
    "marketCap": 2380096768,
    "fiftyTwoWeekHigh": 158.61,
    "fiftyTwoWeekLow": 73.15,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "B. Riley Adjusts Price Target on Axcelis Technologies to $120 From $145, Maintains Buy Rating",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-08 06:33:53",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/b-riley-adjusts-price-target-143353078.html"
      },
      {
        "title": "Benchmark Downgrades Axcelis Technologies to Hold",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-08 05:28:54",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/benchmark-downgrades-axcelis-technologies-hold-132854236.html"
      },
      {
        "title": "Axcelis Technologies, Inc. (NASDAQ:ACLS) Just Reported, And Analysts Assigned A US$133 Price Target",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-08 04:37:35",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/axcelis-technologies-inc-nasdaq-acls-123735021.html"
      },
      {
        "title": "Axcelis Technologies Inc (ACLS) Q3 2024 Earnings Call Highlights: Strong Revenue Amid Market ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-07 23:11:35",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/axcelis-technologies-inc-acls-q3-071135651.html"
      },
      {
        "title": "Axcelis Technologies (ACLS) Surpasses Q3 Earnings and Revenue Estimates",
        "publisher": "Zacks",
        "timestamp": "2024-11-06 14:15:13",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/axcelis-technologies-acls-surpasses-q3-221513962.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 5,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "IDYA",
    "timestamp": "2024-11-17 14:46:17",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 26.61,
    "priceChange": -9.7,
    "openPrice": 29.46,
    "prevClose": 29.47,
    "dayHigh": 29.79,
    "dayLow": 26.41,
    "volume": 1197800,
    "prevVolume": 723400,
    "averageVolume": 734978.8888888889,
    "volumeChange": 65.58,
    "volumeVsAvg": 62.97,
    "recentVolumes": [
      602400,
      540600,
      472800,
      723400,
      1197800
    ],
    "marketCap": 2302543104,
    "fiftyTwoWeekHigh": 47.73,
    "fiftyTwoWeekLow": 26.41,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day",
        "publisher": "PR Newswire",
        "timestamp": "2024-11-12 03:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ideaya-biosciences-announces-participation-jefferies-110000253.html"
      },
      {
        "title": "IDEAYA Biosciences Exercises Option to Develop Biocytogen's Potential Cancer Treatment",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-11 03:59:19",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ideaya-biosciences-exercises-option-develop-115919116.html"
      },
      {
        "title": "Biocytogen Announces IDEAYA\u2019s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise",
        "publisher": "Business Wire",
        "timestamp": "2024-11-11 03:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/biocytogen-announces-ideaya-nomination-development-110000126.html"
      },
      {
        "title": "IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen",
        "publisher": "PR Newswire",
        "timestamp": "2024-11-11 03:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ideaya-announces-development-candidate-nomination-110000661.html"
      },
      {
        "title": "Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's  What You Should Know",
        "publisher": "Zacks",
        "timestamp": "2024-11-07 06:55:12",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/wall-street-analysts-predict-81-145512255.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 5,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "RYTM",
    "timestamp": "2024-11-17 14:46:17",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 56.22,
    "priceChange": -5.94,
    "openPrice": 60.21,
    "prevClose": 59.77,
    "dayHigh": 60.21,
    "dayLow": 55.82,
    "volume": 690300,
    "prevVolume": 504700,
    "averageVolume": 471312.22222222225,
    "volumeChange": 36.77,
    "volumeVsAvg": 46.46,
    "recentVolumes": [
      1118700,
      398800,
      849900,
      504700,
      690300
    ],
    "marketCap": 3455732736,
    "fiftyTwoWeekHigh": 68.58,
    "fiftyTwoWeekLow": 31.52,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Rhythm Pharmaceuticals Announces Publication of\u00a0Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-13 15:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/rhythm-pharmaceuticals-announces-publication-results-233000908.html"
      },
      {
        "title": "Rhythm Pharmaceuticals Announces New Employment Inducement Grants",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-13 13:01:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/rhythm-pharmaceuticals-announces-employment-inducement-210100629.html"
      },
      {
        "title": "High Growth Tech Stocks Featuring Three Prominent US Companies",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-12 10:02:52",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/high-growth-tech-stocks-featuring-180252372.html"
      },
      {
        "title": "Rhythm Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-07 04:53:59",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/rhythm-pharmaceuticals-third-quarter-2024-125359829.html"
      },
      {
        "title": "Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-06 23:29:45",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/rhythm-pharmaceuticals-inc-rytm-q3-072945940.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "TWST",
    "timestamp": "2024-11-17 14:46:18",
    "sector": "Healthcare",
    "industry": "Diagnostics & Research",
    "price": 36.88,
    "priceChange": -5.34,
    "openPrice": 39.2,
    "prevClose": 38.96,
    "dayHigh": 39.2,
    "dayLow": 36.76,
    "volume": 2073200,
    "prevVolume": 1248900,
    "averageVolume": 825357.7777777778,
    "volumeChange": 66.0,
    "volumeVsAvg": 151.19,
    "recentVolumes": [
      746700,
      1106700,
      962100,
      1248900,
      2073200
    ],
    "marketCap": 2161237504,
    "fiftyTwoWeekHigh": 60.9,
    "fiftyTwoWeekLow": 23.0,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Twist Bioscience Corp (TWST) Q4 2024 Earnings Report Preview: What To Look For",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-15 19:44:53",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/twist-bioscience-corp-twst-q4-034453496.html"
      },
      {
        "title": "Twist Bioscience to Present at 7th Annual Evercore HealthCONx Conference",
        "publisher": "Business Wire",
        "timestamp": "2024-11-14 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/twist-bioscience-present-7th-annual-130000338.html"
      },
      {
        "title": "Twist Bioscience Insider Sold Shares Worth $496,299, According to a Recent SEC Filing",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-13 14:30:21",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/twist-bioscience-insider-sold-shares-223021879.html"
      },
      {
        "title": "Twist Bioscience Insider Sold Shares Worth $382,448, According to a Recent SEC Filing",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-13 14:29:47",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/twist-bioscience-insider-sold-shares-222947031.html"
      },
      {
        "title": "Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)",
        "publisher": "Business Wire",
        "timestamp": "2024-11-07 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/twist-bioscience-corporation-announces-inducement-210500126.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 5,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "STEM",
    "timestamp": "2024-11-17 14:46:18",
    "sector": "Utilities",
    "industry": "Utilities - Renewable",
    "price": 0.35,
    "priceChange": -4.32,
    "openPrice": 0.38,
    "prevClose": 0.37,
    "dayHigh": 0.38,
    "dayLow": 0.35,
    "volume": 6911100,
    "prevVolume": 3749500,
    "averageVolume": 6935548.888888889,
    "volumeChange": 84.32,
    "volumeVsAvg": -0.35,
    "recentVolumes": [
      7704700,
      7706900,
      9488900,
      3749500,
      6911100
    ],
    "marketCap": 57452160,
    "fiftyTwoWeekHigh": 4.3,
    "fiftyTwoWeekLow": 0.3,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Stem, Inc. (NYSE:STEM) Analysts Just Cut Their EPS Forecasts Substantially",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-04 02:40:40",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/stem-inc-nyse-stem-analysts-104040650.html"
      },
      {
        "title": "Stem Third Quarter 2024 Earnings: Misses Expectations",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-02 07:08:41",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/stem-third-quarter-2024-earnings-140841462.html"
      },
      {
        "title": "Are Stem, Inc. (NYSE:STEM) Investors Paying Above The Intrinsic Value?",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-01 05:26:31",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/stem-inc-nyse-stem-investors-122631341.html"
      },
      {
        "title": "Stem Announces Third Quarter 2024 Results",
        "publisher": "Business Wire",
        "timestamp": "2024-10-30 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/stem-announces-third-quarter-2024-200500334.html"
      },
      {
        "title": "Stem Appoints Albert Hofeldt as Chief Technology Officer",
        "publisher": "Business Wire",
        "timestamp": "2024-10-23 05:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/stem-appoints-albert-hofeldt-chief-123000839.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "GERN",
    "timestamp": "2024-11-17 14:46:19",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 3.66,
    "priceChange": -1.21,
    "openPrice": 3.72,
    "prevClose": 3.71,
    "dayHigh": 3.78,
    "dayLow": 3.63,
    "volume": 10516500,
    "prevVolume": 10041600,
    "averageVolume": 8974231.111111112,
    "volumeChange": 4.73,
    "volumeVsAvg": 17.19,
    "recentVolumes": [
      8361800,
      11414700,
      11956400,
      10041600,
      10516500
    ],
    "marketCap": 2212473600,
    "fiftyTwoWeekHigh": 5.34,
    "fiftyTwoWeekLow": 1.64,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development",
        "publisher": "Business Wire",
        "timestamp": "2024-11-11 13:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/geron-corporation-announces-appointment-joseph-213000601.html"
      },
      {
        "title": "Geron to Participate in the Stifel 2024 Healthcare Conference",
        "publisher": "Business Wire",
        "timestamp": "2024-11-11 06:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/geron-participate-stifel-2024-healthcare-140000917.html"
      },
      {
        "title": "Analysts Are Upgrading Geron Corporation (NASDAQ:GERN) After Its Latest Results",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-10 05:56:41",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/analysts-upgrading-geron-corporation-nasdaq-135641880.html"
      },
      {
        "title": "Geron Third Quarter 2024 Earnings: Beats Expectations",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-09 04:15:13",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/geron-third-quarter-2024-earnings-121513264.html"
      },
      {
        "title": "Geron Corp (GERN) Q3 2024 Earnings Call Highlights: Strong Rytelo Launch and Strategic ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-08 05:00:41",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/geron-corp-gern-q3-2024-130041252.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "VIR",
    "timestamp": "2024-11-17 14:46:20",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 8.0,
    "priceChange": -7.41,
    "openPrice": 8.7,
    "prevClose": 8.64,
    "dayHigh": 8.7,
    "dayLow": 7.86,
    "volume": 1480700,
    "prevVolume": 766100,
    "averageVolume": 906801.1111111111,
    "volumeChange": 93.28,
    "volumeVsAvg": 63.29,
    "recentVolumes": [
      817400,
      1087700,
      697200,
      766100,
      1480700
    ],
    "marketCap": 1103137280,
    "fiftyTwoWeekHigh": 13.09,
    "fiftyTwoWeekLow": 7.12,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday?",
        "publisher": "Benzinga",
        "timestamp": "2024-11-15 10:39:33",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/whats-going-liver-disease-focused-183933781.html"
      },
      {
        "title": "Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting",
        "publisher": "Business Wire",
        "timestamp": "2024-11-15 08:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/vir-biotechnology-announces-positive-end-160000726.html"
      },
      {
        "title": "Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-04 02:46:51",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/analysts-lowered-expectations-vir-biotechnology-104651751.html"
      },
      {
        "title": "Vir Biotechnology Third Quarter 2024 Earnings: Misses Expectations",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-02 07:58:03",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/vir-biotechnology-third-quarter-2024-145803534.html"
      },
      {
        "title": "Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-01 14:01:08",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/vir-biotechnology-inc-vir-q3-210108073.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 5,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ALKS",
    "timestamp": "2024-11-17 14:46:20",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "price": 28.2,
    "priceChange": -0.53,
    "openPrice": 28.41,
    "prevClose": 28.35,
    "dayHigh": 28.41,
    "dayLow": 27.63,
    "volume": 2053800,
    "prevVolume": 1144000,
    "averageVolume": 1793232.2222222222,
    "volumeChange": 79.53,
    "volumeVsAvg": 14.53,
    "recentVolumes": [
      1875300,
      1545700,
      1523300,
      1144000,
      2053800
    ],
    "marketCap": 4561226752,
    "fiftyTwoWeekHigh": 32.88,
    "fiftyTwoWeekLow": 22.22,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks",
        "publisher": "Investor's Business Daily",
        "timestamp": "2024-11-15 10:36:38",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/646ae987-4a1c-35a8-8f94-7bfeaae7f4cf/the-cream-of-the-crop%3A-5.html"
      },
      {
        "title": "Alkermes Insider Sold Shares Worth $1,774,576, According to a Recent SEC Filing",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-12 13:53:05",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/alkermes-insider-sold-shares-worth-215305594.html"
      },
      {
        "title": "Alkermes to Participate in Two Upcoming Investor Conferences",
        "publisher": "PR Newswire",
        "timestamp": "2024-11-11 13:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/alkermes-participate-two-upcoming-investor-210000349.html"
      },
      {
        "title": "Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences",
        "publisher": "PR Newswire",
        "timestamp": "2024-11-07 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/alkermes-highlights-presentations-across-neuroscience-120000390.html"
      },
      {
        "title": "Stifel Upgrades Alkermes to Buy From Hold, Adjusts Price Target to $36 From $25",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-05 04:56:14",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/stifel-upgrades-alkermes-buy-hold-125614853.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "AMPH",
    "timestamp": "2024-11-17 14:46:21",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "price": 44.58,
    "priceChange": -1.07,
    "openPrice": 45.06,
    "prevClose": 45.06,
    "dayHigh": 45.39,
    "dayLow": 43.88,
    "volume": 408700,
    "prevVolume": 359000,
    "averageVolume": 362658.8888888889,
    "volumeChange": 13.84,
    "volumeVsAvg": 12.7,
    "recentVolumes": [
      382500,
      364200,
      421200,
      359000,
      408700
    ],
    "marketCap": 2144911232,
    "fiftyTwoWeekHigh": 65.92,
    "fiftyTwoWeekLow": 36.56,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference",
        "publisher": "ACCESSWIRE",
        "timestamp": "2024-11-13 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/amphastar-pharmaceuticals-present-jefferies-london-210500544.html"
      },
      {
        "title": "Amphastar Pharmaceuticals Third Quarter 2024 Earnings: Misses Expectations",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-08 02:17:46",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/amphastar-pharmaceuticals-third-quarter-2024-101746145.html"
      },
      {
        "title": "Q3 2024 Amphastar Pharmaceuticals Inc Earnings Call",
        "publisher": "Thomson Reuters StreetEvents",
        "timestamp": "2024-11-07 10:18:48",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/q3-2024-amphastar-pharmaceuticals-inc-181848368.html"
      },
      {
        "title": "Amphastar Pharmaceuticals Inc (AMPH) Q3 2024 Earnings Call Highlights: Resilient Revenue Growth ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-06 23:24:33",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/amphastar-pharmaceuticals-inc-amph-q3-072433664.html"
      },
      {
        "title": "Here's What Key Metrics Tell Us About Amphastar (AMPH) Q3 Earnings",
        "publisher": "Zacks",
        "timestamp": "2024-11-06 15:00:12",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/heres-key-metrics-tell-us-230012936.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "SVRA",
    "timestamp": "2024-11-17 14:46:22",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 2.97,
    "priceChange": -6.74,
    "openPrice": 3.21,
    "prevClose": 3.19,
    "dayHigh": 3.22,
    "dayLow": 2.83,
    "volume": 3586600,
    "prevVolume": 1608400,
    "averageVolume": 1188573.3333333333,
    "volumeChange": 122.99,
    "volumeVsAvg": 201.76,
    "recentVolumes": [
      901300,
      1050200,
      3176500,
      1608400,
      3586600
    ],
    "marketCap": 511424640,
    "fiftyTwoWeekHigh": 5.7,
    "fiftyTwoWeekLow": 2.83,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-13 10:21:26",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/evercore-downgrades-savara-manufacturing-concerns-182126627.html"
      },
      {
        "title": "Savara Announces Participation in Upcoming Healthcare Conferences",
        "publisher": "Business Wire",
        "timestamp": "2024-11-13 05:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/savara-announces-participation-upcoming-healthcare-130500395.html"
      },
      {
        "title": "Savara Reports Third Quarter 2024 Financial Results and Provides Business Update",
        "publisher": "Business Wire",
        "timestamp": "2024-11-12 05:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/savara-reports-third-quarter-2024-130500652.html"
      },
      {
        "title": "Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference",
        "publisher": "Business Wire",
        "timestamp": "2024-11-04 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/savara-present-guggenheim-inaugural-healthcare-210500663.html"
      },
      {
        "title": "Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of \"The Balancing Act\u00ae\" Airing on Lifetime\u00ae TV",
        "publisher": "Business Wire",
        "timestamp": "2024-10-22 05:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/savara-announces-rare-lung-disease-120500648.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 5,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "GH",
    "timestamp": "2024-11-17 14:46:22",
    "sector": "Healthcare",
    "industry": "Diagnostics & Research",
    "price": 29.1,
    "priceChange": -3.67,
    "openPrice": 30.58,
    "prevClose": 30.21,
    "dayHigh": 30.67,
    "dayLow": 28.98,
    "volume": 3002000,
    "prevVolume": 2021400,
    "averageVolume": 2180551.111111111,
    "volumeChange": 48.51,
    "volumeVsAvg": 37.67,
    "recentVolumes": [
      1913000,
      1922400,
      2929400,
      2021400,
      3002000
    ],
    "marketCap": 3596686080,
    "fiftyTwoWeekHigh": 37.04,
    "fiftyTwoWeekLow": 15.81,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
        "publisher": "Business Wire",
        "timestamp": "2024-11-13 14:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/guardant-health-announces-inducement-grants-220500617.html"
      },
      {
        "title": "Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought",
        "publisher": "Motley Fool",
        "timestamp": "2024-11-12 08:55:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/14f8cd6f-673a-3eed-903e-d6131dec7e01/cathie-wood-goes-bargain.html"
      },
      {
        "title": "Guardant Health Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-08 04:35:24",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/guardant-health-third-quarter-2024-123524903.html"
      },
      {
        "title": "Why Guardant Health Stock Blasted 13% Higher on Thursday",
        "publisher": "Motley Fool",
        "timestamp": "2024-11-07 14:37:59",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/d80ac4c7-c1c5-32ec-8811-d97a2cc08723/why-guardant-health-stock.html"
      },
      {
        "title": "Guardant Health Pops 13% On An 'Impressive' Beat Following Exact Sciences' Flop",
        "publisher": "Investor's Business Daily",
        "timestamp": "2024-11-07 13:05:11",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/e51c6c8b-4ec7-3e91-875f-9780e07fefad/guardant-health-pops-13%25-on.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "NTLA",
    "timestamp": "2024-11-17 14:46:23",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 13.96,
    "priceChange": -7.67,
    "openPrice": 15.31,
    "prevClose": 15.12,
    "dayHigh": 15.31,
    "dayLow": 13.95,
    "volume": 3674300,
    "prevVolume": 2125200,
    "averageVolume": 1842714.4444444445,
    "volumeChange": 72.89,
    "volumeVsAvg": 99.4,
    "recentVolumes": [
      2566500,
      2638800,
      2106800,
      2125200,
      3674300
    ],
    "marketCap": 1422830592,
    "fiftyTwoWeekHigh": 34.87,
    "fiftyTwoWeekLow": 13.95,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in\u00a0Transthyretin (ATTR) Amyloidosis",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-16 07:16:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/intellia-announces-first-clinical-evidence-151600829.html"
      },
      {
        "title": "Truist Securities Cuts Price Target on Intellia Therapeutics to $90 From $120, Maintains Buy Rating",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-11 04:37:45",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/truist-securities-cuts-price-target-123745954.html"
      },
      {
        "title": "Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-09 06:44:02",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/intellia-therapeutics-inc-nasdaq-ntla-144402595.html"
      },
      {
        "title": "Intellia Therapeutics Inc (NTLA) Q3 2024 Earnings Call Highlights: Financial Stability and ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-08 09:01:08",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/intellia-therapeutics-inc-ntla-q3-170108276.html"
      },
      {
        "title": "NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus",
        "publisher": "Zacks",
        "timestamp": "2024-11-08 06:49:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ntlas-q3-earnings-revenues-beat-144900731.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 5,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "SRPT",
    "timestamp": "2024-11-17 14:46:26",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 104.58,
    "priceChange": -4.15,
    "openPrice": 108.54,
    "prevClose": 109.11,
    "dayHigh": 108.62,
    "dayLow": 102.57,
    "volume": 1570800,
    "prevVolume": 1453100,
    "averageVolume": 987178.8888888889,
    "volumeChange": 8.1,
    "volumeVsAvg": 59.12,
    "recentVolumes": [
      1143400,
      1110100,
      961900,
      1453100,
      1570800
    ],
    "marketCap": 9985618944,
    "fiftyTwoWeekHigh": 173.25,
    "fiftyTwoWeekLow": 78.67,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Sarepta Therapeutics, Inc. (SRPT): Among 12 High Growth Large Cap Stocks to Buy Now",
        "publisher": "Insider Monkey",
        "timestamp": "2024-11-15 09:26:25",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/sarepta-therapeutics-inc-srpt-among-172625193.html"
      },
      {
        "title": "Why Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Are Weaker Than They Seem",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-13 02:25:59",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/why-sarepta-therapeutics-nasdaq-srpt-102559244.html"
      },
      {
        "title": "Sarepta recent weakness brings buying opportunity, says JPMorgan",
        "publisher": "TipRanks",
        "timestamp": "2024-11-12 03:56:38",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/sarepta-recent-weakness-brings-buying-115638070.html"
      },
      {
        "title": "Sarepta price target lowered to $193 from $200 at Baird",
        "publisher": "TipRanks",
        "timestamp": "2024-11-08 03:57:31",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/sarepta-price-target-lowered-193-115731440.html"
      },
      {
        "title": "SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program",
        "publisher": "Zacks",
        "timestamp": "2024-11-07 06:19:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/srpt-beats-q3-earnings-sales-141900711.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "RARE",
    "timestamp": "2024-11-17 14:46:27",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 44.75,
    "priceChange": -6.07,
    "openPrice": 47.36,
    "prevClose": 47.64,
    "dayHigh": 48.11,
    "dayLow": 44.53,
    "volume": 818900,
    "prevVolume": 586300,
    "averageVolume": 738492.2222222222,
    "volumeChange": 39.67,
    "volumeVsAvg": 10.89,
    "recentVolumes": [
      1060600,
      857000,
      1091300,
      586300,
      818900
    ],
    "marketCap": 4132407552,
    "fiftyTwoWeekHigh": 60.37,
    "fiftyTwoWeekLow": 37.02,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST\u2019s 17th Annual Global Science Summit",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-09 07:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ultragenyx-presents-positive-gtx-102-153000502.html"
      },
      {
        "title": "Ultragenyx Pharmaceutical Third Quarter 2024 Earnings: Beats Expectations",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-07 04:05:05",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ultragenyx-pharmaceutical-third-quarter-2024-120505280.html"
      },
      {
        "title": "Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates",
        "publisher": "Zacks",
        "timestamp": "2024-11-06 06:42:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ultragenyx-q3-loss-narrower-expected-144200575.html"
      },
      {
        "title": "Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings Call Highlights: Robust Revenue Growth ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-05 23:27:51",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ultragenyx-pharmaceutical-inc-rare-q3-072751317.html"
      },
      {
        "title": "Ultragenyx Pharmaceutical Q3 Net Loss Narrows, Revenue Rises; Shares Fall After Hours",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-05 14:05:09",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ultragenyx-pharmaceutical-q3-net-loss-220509723.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "TRVI",
    "timestamp": "2024-11-17 14:46:27",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 2.75,
    "priceChange": -3.85,
    "openPrice": 2.9,
    "prevClose": 2.86,
    "dayHigh": 2.9,
    "dayLow": 2.67,
    "volume": 500300,
    "prevVolume": 1099000,
    "averageVolume": 352961.1111111111,
    "volumeChange": -54.48,
    "volumeVsAvg": 41.74,
    "recentVolumes": [
      1666900,
      307400,
      288500,
      1099000,
      500300
    ],
    "marketCap": 211380672,
    "fiftyTwoWeekHigh": 4.0,
    "fiftyTwoWeekLow": 0.97,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Q3 2024 Trevi Therapeutics Inc Earnings Call",
        "publisher": "Thomson Reuters StreetEvents",
        "timestamp": "2024-11-07 10:18:18",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/q3-2024-trevi-therapeutics-inc-181818063.html"
      },
      {
        "title": "Trevi Therapeutics Inc (TRVI) Q3 2024 Earnings Call Highlights: Navigating Increased Losses and ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-06 23:21:54",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/trevi-therapeutics-inc-trvi-q3-072154745.html"
      },
      {
        "title": "Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates",
        "publisher": "PR Newswire",
        "timestamp": "2024-11-06 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/trevi-therapeutics-reports-third-quarter-210500794.html"
      },
      {
        "title": "Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024",
        "publisher": "PR Newswire",
        "timestamp": "2024-10-30 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/trevi-therapeutics-report-third-quarter-200500998.html"
      },
      {
        "title": "Rosalind Advisors, Inc. Reduces Stake in Trevi Therapeutics Inc.",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-10-23 14:02:08",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/rosalind-advisors-inc-reduces-stake-210208755.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "PGEN",
    "timestamp": "2024-11-17 14:46:28",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 0.82,
    "priceChange": -6.81,
    "openPrice": 0.91,
    "prevClose": 0.88,
    "dayHigh": 0.92,
    "dayLow": 0.78,
    "volume": 1777600,
    "prevVolume": 584500,
    "averageVolume": 939922.2222222222,
    "volumeChange": 204.12,
    "volumeVsAvg": 89.12,
    "recentVolumes": [
      1161100,
      1222600,
      645300,
      584500,
      1777600
    ],
    "marketCap": 239995696,
    "fiftyTwoWeekHigh": 1.93,
    "fiftyTwoWeekLow": 0.78,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Precigen Reports Third Quarter 2024 Financial Results and Business Updates",
        "publisher": "PR Newswire",
        "timestamp": "2024-11-14 13:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/precigen-reports-third-quarter-2024-213000630.html"
      },
      {
        "title": "Precigen to Participate in the Stifel 2024 Healthcare Conference",
        "publisher": "PR Newswire",
        "timestamp": "2024-11-12 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/precigen-participate-stifel-2024-healthcare-210500199.html"
      },
      {
        "title": "High Growth Tech Stocks To Watch In October 2024",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-10-24 07:04:35",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/high-growth-tech-stocks-watch-140435257.html"
      },
      {
        "title": "Precigen to Participate in the 2024 Cantor Global Healthcare Conference",
        "publisher": "PR Newswire",
        "timestamp": "2024-09-16 13:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/precigen-participate-2024-cantor-global-203000006.html"
      },
      {
        "title": "While institutions own 26% of Precigen, Inc. (NASDAQ:PGEN), private equity firms are its largest shareholders with 43% ownership",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-09-12 05:55:44",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/while-institutions-own-26-precigen-125544351.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 5,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "EVH",
    "timestamp": "2024-11-17 14:46:29",
    "sector": "Healthcare",
    "industry": "Health Information Services",
    "price": 12.37,
    "priceChange": -2.37,
    "openPrice": 12.81,
    "prevClose": 12.67,
    "dayHigh": 12.81,
    "dayLow": 12.18,
    "volume": 3122900,
    "prevVolume": 3091700,
    "averageVolume": 2490777.777777778,
    "volumeChange": 1.01,
    "volumeVsAvg": 25.38,
    "recentVolumes": [
      8474000,
      3745300,
      4747700,
      3091700,
      3122900
    ],
    "marketCap": 1424021888,
    "fiftyTwoWeekHigh": 35.0,
    "fiftyTwoWeekLow": 12.18,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Evolent Health Third Quarter 2024 Earnings: EPS Misses Expectations",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-09 06:20:35",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/evolent-health-third-quarter-2024-142035893.html"
      },
      {
        "title": "Evolent Health downgraded at Stephens amid surging cancer costs",
        "publisher": "TipRanks",
        "timestamp": "2024-11-09 03:42:05",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/evolent-health-downgraded-stephens-amid-114205185.html"
      },
      {
        "title": "Compared to Estimates, Evolent Health (EVH) Q3 Earnings: A Look at Key Metrics",
        "publisher": "Zacks",
        "timestamp": "2024-11-08 12:30:02",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/compared-estimates-evolent-health-evh-203002551.html"
      },
      {
        "title": "Top Midday Decliners",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-08 11:14:53",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/top-midday-decliners-191453438.html"
      },
      {
        "title": "Oppenheimer Adjusts Evolent Health Price Target to $34 From $45, Maintains Outperform Rating",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-08 08:41:54",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/oppenheimer-adjusts-evolent-health-price-164154520.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ARQT",
    "timestamp": "2024-11-17 14:46:29",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 9.25,
    "priceChange": -6.85,
    "openPrice": 9.84,
    "prevClose": 9.93,
    "dayHigh": 10.04,
    "dayLow": 9.11,
    "volume": 3018900,
    "prevVolume": 2171400,
    "averageVolume": 2095078.888888889,
    "volumeChange": 39.03,
    "volumeVsAvg": 44.09,
    "recentVolumes": [
      2034400,
      1724100,
      2280000,
      2171400,
      3018900
    ],
    "marketCap": 1083836672,
    "fiftyTwoWeekHigh": 13.17,
    "fiftyTwoWeekLow": 1.76,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Arcutis\u2019 ZORYVE\u00ae (roflumilast) Awarded Best Eczema Treatment by Glamour",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-13 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/arcutis-zoryve-roflumilast-awarded-best-130000747.html"
      },
      {
        "title": "Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?",
        "publisher": "Zacks",
        "timestamp": "2024-11-11 06:55:11",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/wall-street-analysts-see-70-145511488.html"
      },
      {
        "title": "Arcutis Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-08 02:28:32",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/arcutis-biotherapeutics-third-quarter-2024-102832558.html"
      },
      {
        "title": "Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-06 23:23:14",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/arcutis-biotherapeutics-inc-arqt-q3-072314679.html"
      },
      {
        "title": "Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates",
        "publisher": "Zacks",
        "timestamp": "2024-11-06 14:15:13",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/arcutis-biotherapeutics-inc-arqt-reports-221513250.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "QNRX",
    "timestamp": "2024-11-17 14:46:30",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 0.62,
    "priceChange": 2.17,
    "openPrice": 0.62,
    "prevClose": 0.61,
    "dayHigh": 0.64,
    "dayLow": 0.57,
    "volume": 188600,
    "prevVolume": 144000,
    "averageVolume": 1878263.3333333333,
    "volumeChange": 30.97,
    "volumeVsAvg": -89.96,
    "recentVolumes": [
      327100,
      119300,
      139400,
      144000,
      188600
    ],
    "marketCap": 3131836,
    "fiftyTwoWeekHigh": 6.18,
    "fiftyTwoWeekLow": 0.48,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "QNRX: International Sites Participating in QRX003 NS Study, Studying QRX003 for Additional Diseases, in Younger Populations",
        "publisher": "Zacks Small Cap Research",
        "timestamp": "2024-11-12 03:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/qnrx-international-sites-participating-qrx003-110000612.html"
      },
      {
        "title": "Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-07 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/quoin-pharmaceuticals-provides-corporate-announces-130000567.html"
      },
      {
        "title": "Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-05 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/quoin-pharmaceuticals-initiates-clinical-testing-130000249.html"
      },
      {
        "title": "Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-31 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/quoin-pharmaceuticals-announce-third-quarter-200500797.html"
      },
      {
        "title": "Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-22 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/quoin-pharmaceuticals-announces-further-international-120000210.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "SYRS",
    "timestamp": "2024-11-17 14:46:31",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 0.26,
    "priceChange": -5.75,
    "openPrice": 0.27,
    "prevClose": 0.28,
    "dayHigh": 0.28,
    "dayLow": 0.25,
    "volume": 6288900,
    "prevVolume": 17314300,
    "averageVolume": 1154826.6666666667,
    "volumeChange": -63.68,
    "volumeVsAvg": 444.58,
    "recentVolumes": [
      1016600,
      10383800,
      38529100,
      17314300,
      6288900
    ],
    "marketCap": 6957667,
    "fiftyTwoWeekHigh": 8.17,
    "fiftyTwoWeekLow": 0.25,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal",
        "publisher": "Zacks",
        "timestamp": "2024-11-14 07:24:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/syros-stock-plunges-lead-cancer-152400773.html"
      },
      {
        "title": "Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright",
        "publisher": "TipRanks",
        "timestamp": "2024-11-14 03:35:45",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/syros-pharmaceuticals-downgraded-neutral-buy-113545652.html"
      },
      {
        "title": "Syros stock craters after lead cancer therapy flops in Phase III trial",
        "publisher": "Clinical Trials Arena",
        "timestamp": "2024-11-13 04:27:43",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/45f00e8c-ebc8-3f5f-ac36-f401e187ec2c/syros-stock-craters-after.html"
      },
      {
        "title": "Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression",
        "publisher": "Business Wire",
        "timestamp": "2024-11-12 13:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/syros-announces-topline-data-select-213000645.html"
      },
      {
        "title": "Syros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023)",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-02 07:20:52",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/syros-pharmaceuticals-third-quarter-2024-142052866.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "MNKD",
    "timestamp": "2024-11-17 14:46:31",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 6.81,
    "priceChange": -2.99,
    "openPrice": 7.05,
    "prevClose": 7.02,
    "dayHigh": 7.07,
    "dayLow": 6.62,
    "volume": 5215700,
    "prevVolume": 3426600,
    "averageVolume": 2502558.888888889,
    "volumeChange": 52.21,
    "volumeVsAvg": 108.41,
    "recentVolumes": [
      3628100,
      2927400,
      2416300,
      3426600,
      5215700
    ],
    "marketCap": 1875290368,
    "fiftyTwoWeekHigh": 7.63,
    "fiftyTwoWeekLow": 3.17,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "MannKind Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-09 05:13:12",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mannkind-third-quarter-2024-earnings-131312659.html"
      },
      {
        "title": "Q3 2024 MannKind Corp Earnings Call",
        "publisher": "Thomson Reuters StreetEvents",
        "timestamp": "2024-11-08 10:26:05",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/q3-2024-mannkind-corp-earnings-182605252.html"
      },
      {
        "title": "MannKind Corp (MNKD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-07 23:28:39",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mannkind-corp-mnkd-q3-2024-072839216.html"
      },
      {
        "title": "MannKind (MNKD) Q3 2024 Earnings Call Transcript",
        "publisher": "Motley Fool",
        "timestamp": "2024-11-07 20:15:18",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/8a98dfd7-d29d-3206-9063-f9f5dad82f17/mannkind-%28mnkd%29-q3-2024.html"
      },
      {
        "title": "MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say",
        "publisher": "Zacks",
        "timestamp": "2024-11-07 16:00:08",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mannkind-mnkd-reports-q3-earnings-000008528.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "XERS",
    "timestamp": "2024-11-17 14:46:32",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 2.91,
    "priceChange": -4.43,
    "openPrice": 3.07,
    "prevClose": 3.05,
    "dayHigh": 3.07,
    "dayLow": 2.91,
    "volume": 1923900,
    "prevVolume": 1477800,
    "averageVolume": 1590673.3333333333,
    "volumeChange": 30.19,
    "volumeVsAvg": 20.95,
    "recentVolumes": [
      2426600,
      3684900,
      2433800,
      1477800,
      1923900
    ],
    "marketCap": 435316512,
    "fiftyTwoWeekHigh": 3.64,
    "fiftyTwoWeekLow": 1.69,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Analysts Expect Breakeven For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Before Long",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-17 04:57:41",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/analysts-expect-breakeven-xeris-biopharma-125741335.html"
      },
      {
        "title": "Piper Sandler Downgrades Xeris Biopharma to Neutral From Overweight, $3 Price Target",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-11 04:25:25",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/piper-sandler-downgrades-xeris-biopharma-122525950.html"
      },
      {
        "title": "Xeris Biopharma Holdings Inc (XERS) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-08 23:06:11",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/xeris-biopharma-holdings-inc-xers-070611455.html"
      },
      {
        "title": "Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates",
        "publisher": "Zacks",
        "timestamp": "2024-11-08 06:30:10",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/xeris-biopharma-xers-q3-earnings-143010959.html"
      },
      {
        "title": "Xeris Biopharma (XERS) Reports Q3 Loss, Tops Revenue Estimates",
        "publisher": "Zacks",
        "timestamp": "2024-11-08 05:10:03",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/xeris-biopharma-xers-reports-q3-131003367.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "SNDX",
    "timestamp": "2024-11-17 14:46:33",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 15.84,
    "priceChange": -5.66,
    "openPrice": 16.91,
    "prevClose": 16.79,
    "dayHigh": 16.91,
    "dayLow": 15.74,
    "volume": 4956800,
    "prevVolume": 2186300,
    "averageVolume": 1146732.2222222222,
    "volumeChange": 126.72,
    "volumeVsAvg": 332.25,
    "recentVolumes": [
      923200,
      8373200,
      3071800,
      2186300,
      4956800
    ],
    "marketCap": 1351212288,
    "fiftyTwoWeekHigh": 25.34,
    "fiftyTwoWeekLow": 14.96,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Syndax Announces FDA Approval of Revuforj\u00ae (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation",
        "publisher": "PR Newswire",
        "timestamp": "2024-11-15 14:29:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/syndax-announces-fda-approval-revuforj-222900623.html"
      },
      {
        "title": "Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data",
        "publisher": "Zacks",
        "timestamp": "2024-11-14 11:16:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/biotech-stock-roundup-nvax-q3-191600128.html"
      },
      {
        "title": "Syndax\u2019s stock sinks by 25% despite AML trial meeting primary endpoint",
        "publisher": "Pharmaceutical Technology",
        "timestamp": "2024-11-13 10:06:14",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/9539ab48-10a0-37b9-8015-20df983804d1/syndax%E2%80%99s-stock-sinks-by-25%25.html"
      },
      {
        "title": "Syndax\u2019s revumenib meets primary results in AML trial",
        "publisher": "TipRanks",
        "timestamp": "2024-11-13 04:21:35",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/syndax-revumenib-meets-primary-results-122135013.html"
      },
      {
        "title": "Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer",
        "publisher": "Benzinga",
        "timestamp": "2024-11-12 10:07:18",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/syndax-pharmaceuticals-stock-falls-data-180718829.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 5,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "PLRX",
    "timestamp": "2024-11-17 14:46:36",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 12.41,
    "priceChange": -3.42,
    "openPrice": 12.9,
    "prevClose": 12.85,
    "dayHigh": 12.9,
    "dayLow": 11.76,
    "volume": 741200,
    "prevVolume": 1200400,
    "averageVolume": 432787.77777777775,
    "volumeChange": -38.25,
    "volumeVsAvg": 71.26,
    "recentVolumes": [
      326500,
      338000,
      251000,
      1200400,
      741200
    ],
    "marketCap": 756410240,
    "fiftyTwoWeekHigh": 19.62,
    "fiftyTwoWeekLow": 10.22,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-07 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/pliant-therapeutics-provides-corporate-reports-210500264.html"
      },
      {
        "title": "Pliant Therapeutics to Participate in the Stifel Healthcare Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-06 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/pliant-therapeutics-participate-stifel-healthcare-130000876.html"
      },
      {
        "title": "Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis\u00a0to be Highlighted in a Late-Breaking Presentation at The Liver Meeting\u00ae 2024",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-17 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/pliant-therapeutics-integris-psc-phase-120000300.html"
      },
      {
        "title": "Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-10-04 18:03:09",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/paradigm-biocapital-advisors-lp-acquires-010309493.html"
      },
      {
        "title": "Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-01 13:35:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/pliant-therapeutics-appoints-gary-palmer-203500337.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "MREO",
    "timestamp": "2024-11-17 14:46:36",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 3.53,
    "priceChange": -7.72,
    "openPrice": 3.79,
    "prevClose": 3.82,
    "dayHigh": 3.8,
    "dayLow": 3.51,
    "volume": 2139400,
    "prevVolume": 1561500,
    "averageVolume": 820077.7777777778,
    "volumeChange": 37.01,
    "volumeVsAvg": 160.88,
    "recentVolumes": [
      442400,
      973500,
      964200,
      1561500,
      2139400
    ],
    "marketCap": 547665344,
    "fiftyTwoWeekHigh": 5.02,
    "fiftyTwoWeekLow": 1.86,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-14 04:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mereo-biopharma-participate-fireside-chat-123000135.html"
      },
      {
        "title": "Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-12 04:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mereo-biopharma-reports-third-quarter-123000883.html"
      },
      {
        "title": "Is Mereo BioPharma Group (MREO) the Hottest Penny Stock to Invest in According to Hedge Funds?",
        "publisher": "Insider Monkey",
        "timestamp": "2024-10-16 06:06:06",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mereo-biopharma-group-mreo-hottest-130606150.html"
      },
      {
        "title": "Mereo BioPharma Group plc (MREO): A Bull Case Theory",
        "publisher": "Insider Monkey",
        "timestamp": "2024-09-18 05:21:06",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mereo-biopharma-group-plc-mreo-122106428.html"
      },
      {
        "title": "Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-09-12 14:35:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mereo-biopharma-participate-fireside-chat-213500356.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 5,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "MDGL",
    "timestamp": "2024-11-17 14:46:37",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 288.9,
    "priceChange": -4.55,
    "openPrice": 303.29,
    "prevClose": 302.67,
    "dayHigh": 303.29,
    "dayLow": 272.72,
    "volume": 944400,
    "prevVolume": 405300,
    "averageVolume": 357456.6666666667,
    "volumeChange": 133.01,
    "volumeVsAvg": 164.2,
    "recentVolumes": [
      331700,
      374200,
      505100,
      405300,
      944400
    ],
    "marketCap": 6294045184,
    "fiftyTwoWeekHigh": 368.29,
    "fiftyTwoWeekLow": 168.25,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "John Paulson's Strategic Moves in Q3 2024: A Focus on Anglogold Ashanti PLC",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-14 18:12:02",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/john-paulsons-strategic-moves-q3-021202353.html"
      },
      {
        "title": "Zacks Industry Outlook Madrigal, Corcept, Catalyst  Larimar and  Theravance",
        "publisher": "Zacks",
        "timestamp": "2024-11-11 04:47:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/zacks-industry-outlook-madrigal-corcept-124700319.html"
      },
      {
        "title": "1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More",
        "publisher": "Motley Fool",
        "timestamp": "2024-11-10 06:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/8bce74f9-7a66-357e-a50a-a862d618df59/1-growing-biotech-stock-to.html"
      },
      {
        "title": "5 Small Drug Stocks to Buy as Trump Gets Re-Elected",
        "publisher": "Zacks",
        "timestamp": "2024-11-08 04:18:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/5-small-drug-stocks-buy-121800348.html"
      },
      {
        "title": "3 High Growth Tech Stocks Leading The US Market",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-07 06:10:48",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/3-high-growth-tech-stocks-141048086.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "KZR",
    "timestamp": "2024-11-17 14:46:38",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 7.49,
    "priceChange": -0.4,
    "openPrice": 7.45,
    "prevClose": 7.52,
    "dayHigh": 7.51,
    "dayLow": 7.29,
    "volume": 46500,
    "prevVolume": 14800,
    "averageVolume": 77291.55555555556,
    "volumeChange": 214.19,
    "volumeVsAvg": -39.84,
    "recentVolumes": [
      35900,
      42300,
      35900,
      14800,
      46500
    ],
    "marketCap": 54429800,
    "fiftyTwoWeekHigh": 11.4,
    "fiftyTwoWeekLow": 5.2,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Kezar struck again with second FDA hold",
        "publisher": "Clinical Trials Arena",
        "timestamp": "2024-11-13 09:30:44",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/cdcea067-689e-3f71-b98d-620d901d10b5/kezar-struck-again-with.html"
      },
      {
        "title": "Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update",
        "publisher": "Business Wire",
        "timestamp": "2024-11-12 13:01:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/kezar-life-sciences-reports-third-210100311.html"
      },
      {
        "title": "Kezar Life Sciences to Implement 1-for-10 Reverse Stock Split",
        "publisher": "MT Newswires",
        "timestamp": "2024-10-28 07:35:49",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/kezar-life-sciences-implement-1-143549200.html"
      },
      {
        "title": "Kezar Life Sciences Announces 1-for-10 Reverse Stock Split",
        "publisher": "Business Wire",
        "timestamp": "2024-10-28 05:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/kezar-life-sciences-announces-1-123000891.html"
      },
      {
        "title": "Kezar Life Sciences discontinues lupus nephritis programme after fatalities",
        "publisher": "Clinical Trials Arena",
        "timestamp": "2024-10-18 08:02:13",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/1222d6a7-7e98-35df-8959-748cf2ae9d8b/kezar-life-sciences.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "GALT",
    "timestamp": "2024-11-17 14:46:38",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 2.78,
    "priceChange": 1.09,
    "openPrice": 2.8,
    "prevClose": 2.75,
    "dayHigh": 2.88,
    "dayLow": 2.66,
    "volume": 219100,
    "prevVolume": 153800,
    "averageVolume": 128816.66666666667,
    "volumeChange": 42.46,
    "volumeVsAvg": 70.09,
    "recentVolumes": [
      202500,
      116800,
      210500,
      153800,
      219100
    ],
    "marketCap": 172510336,
    "fiftyTwoWeekHigh": 4.27,
    "fiftyTwoWeekLow": 1.56,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-14 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/galectin-therapeutics-reports-financial-results-130000659.html"
      },
      {
        "title": "Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-15 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/galectin-therapeutics-announces-acceptance-three-120000150.html"
      },
      {
        "title": "Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-09-30 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/galectin-therapeutics-participate-h-c-120000552.html"
      },
      {
        "title": "Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-09-03 05:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/galectin-therapeutics-present-h-c-123000283.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ETNB",
    "timestamp": "2024-11-17 14:46:39",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 7.92,
    "priceChange": -9.48,
    "openPrice": 8.85,
    "prevClose": 8.75,
    "dayHigh": 8.85,
    "dayLow": 7.85,
    "volume": 1433600,
    "prevVolume": 1850100,
    "averageVolume": 678668.8888888889,
    "volumeChange": -22.51,
    "volumeVsAvg": 111.24,
    "recentVolumes": [
      516000,
      948300,
      2899400,
      1850100,
      1433600
    ],
    "marketCap": 932425216,
    "fiftyTwoWeekHigh": 16.63,
    "fiftyTwoWeekLow": 7.0,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting\u00ae 2024",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-15 05:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/89bio-presents-analyses-evaluating-pegozafermin-130500115.html"
      },
      {
        "title": "89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-12 20:58:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/89bio-inc-announces-upsized-pricing-045800092.html"
      },
      {
        "title": "89bio, Inc. Announces Proposed Underwritten\u00a0Public Offering of Common Stock and Pre-Funded Warrants",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-12 13:01:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/89bio-inc-announces-proposed-underwritten-210100794.html"
      },
      {
        "title": "89bio Reports Third Quarter 2024 Financial Results and Corporate Updates",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-07 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/89bio-reports-third-quarter-2024-210500824.html"
      },
      {
        "title": "89bio to Participate in the UBS Global Healthcare Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-05 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/89bio-participate-ubs-global-healthcare-210500464.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "CMRX",
    "timestamp": "2024-11-17 14:46:41",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 0.85,
    "priceChange": -5.38,
    "openPrice": 0.89,
    "prevClose": 0.9,
    "dayHigh": 0.89,
    "dayLow": 0.83,
    "volume": 689100,
    "prevVolume": 328700,
    "averageVolume": 395427.77777777775,
    "volumeChange": 109.64,
    "volumeVsAvg": 74.27,
    "recentVolumes": [
      351500,
      221300,
      242200,
      328700,
      689100
    ],
    "marketCap": 77336048,
    "fiftyTwoWeekHigh": 1.3,
    "fiftyTwoWeekLow": 0.75,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-11 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/chimerix-announces-updated-phase-2-120000867.html"
      },
      {
        "title": "Chimerix Third Quarter 2024 Earnings: Misses Expectations",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-09 05:01:45",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/chimerix-third-quarter-2024-earnings-130145817.html"
      },
      {
        "title": "Q3 2024 Chimerix Inc Earnings Call",
        "publisher": "Thomson Reuters StreetEvents",
        "timestamp": "2024-11-07 23:22:14",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/q3-2024-chimerix-inc-earnings-072214376.html"
      },
      {
        "title": "Chimerix Inc (CMRX) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid Financial ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-07 23:12:15",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/chimerix-inc-cmrx-q3-2024-071215089.html"
      },
      {
        "title": "Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates",
        "publisher": "Zacks",
        "timestamp": "2024-11-07 05:35:05",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/chimerix-cmrx-reports-q3-loss-133505561.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 5,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "CDTX",
    "timestamp": "2024-11-17 14:46:41",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 14.5,
    "priceChange": 0.14,
    "openPrice": 14.48,
    "prevClose": 14.48,
    "dayHigh": 14.97,
    "dayLow": 13.9,
    "volume": 31600,
    "prevVolume": 30000,
    "averageVolume": 20432.222222222223,
    "volumeChange": 5.33,
    "volumeVsAvg": 54.66,
    "recentVolumes": [
      10800,
      19400,
      27100,
      30000,
      31600
    ],
    "marketCap": 101260072,
    "fiftyTwoWeekHigh": 24.4,
    "fiftyTwoWeekLow": 10.0,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Cidara Therapeutics: Q3 Earnings Snapshot",
        "publisher": "Associated Press Finance",
        "timestamp": "2024-11-07 14:09:20",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/cidara-therapeutics-q3-earnings-snapshot-220920451.html"
      },
      {
        "title": "Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-31 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/cidara-therapeutics-participate-two-upcoming-120000207.html"
      },
      {
        "title": "Cidara Therapeutics Announces Two Presentations on Drug-Fc Conjugate, CD388, at IDWeek 2024",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-16 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/cidara-therapeutics-announces-two-presentations-120000745.html"
      },
      {
        "title": "Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-04 13:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/cidara-therapeutics-reports-inducement-grant-203000195.html"
      },
      {
        "title": "Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-09-25 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/cidara-therapeutics-announces-two-presentations-120000308.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "GYRE",
    "timestamp": "2024-11-17 14:46:42",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 13.09,
    "priceChange": -5.42,
    "openPrice": 13.8,
    "prevClose": 13.84,
    "dayHigh": 13.8,
    "dayLow": 12.65,
    "volume": 83400,
    "prevVolume": 66400,
    "averageVolume": 53223.333333333336,
    "volumeChange": 25.6,
    "volumeVsAvg": 56.7,
    "recentVolumes": [
      117500,
      164500,
      166000,
      66400,
      83400
    ],
    "marketCap": 1125988608,
    "fiftyTwoWeekHigh": 30.4,
    "fiftyTwoWeekLow": 8.26,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Gyre Therapeutics Third Quarter 2024 Earnings: EPS: US$0.013 (vs US$0.68 loss in 3Q 2023)",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-15 03:27:12",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/gyre-therapeutics-third-quarter-2024-112712072.html"
      },
      {
        "title": "Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-13 03:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/gyre-therapeutics-reports-third-quarter-110000878.html"
      },
      {
        "title": "Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-22 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/gyre-therapeutics-announces-last-patient-200500320.html"
      },
      {
        "title": "Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) market cap dropped US$51m last week; Public companies bore the brunt",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-10-04 07:20:49",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/gyre-therapeutics-inc-nasdaq-gyre-142049369.html"
      },
      {
        "title": "Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-01 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/gyre-therapeutics-present-8th-annual-200500277.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 5,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "AGEN",
    "timestamp": "2024-11-17 14:46:45",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 2.73,
    "priceChange": -1.44,
    "openPrice": 2.83,
    "prevClose": 2.77,
    "dayHigh": 2.88,
    "dayLow": 2.58,
    "volume": 1071900,
    "prevVolume": 935600,
    "averageVolume": 625116.6666666666,
    "volumeChange": 14.57,
    "volumeVsAvg": 71.47,
    "recentVolumes": [
      435300,
      2107400,
      527000,
      935600,
      1071900
    ],
    "marketCap": 63808208,
    "fiftyTwoWeekHigh": 19.69,
    "fiftyTwoWeekLow": 2.58,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround",
        "publisher": "Zacks",
        "timestamp": "2024-11-15 06:35:06",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/down-39-39-4-weeks-143506348.html"
      },
      {
        "title": "Q3 2024 Agenus Inc Earnings Call",
        "publisher": "Thomson Reuters StreetEvents",
        "timestamp": "2024-11-12 23:18:54",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/q3-2024-agenus-inc-earnings-071854589.html"
      },
      {
        "title": "Agenus Inc (AGEN) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges While ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-12 23:08:49",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/agenus-inc-agen-q3-2024-070849016.html"
      },
      {
        "title": "Agenus (AGEN) Q3 2024 Earnings Call Transcript",
        "publisher": "Motley Fool",
        "timestamp": "2024-11-12 09:15:14",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/65ef5d25-8e16-3abd-9317-03c36375d813/agenus-%28agen%29-q3-2024.html"
      },
      {
        "title": "Agenus (AGEN) Reports Q3 Loss, Lags Revenue Estimates",
        "publisher": "Zacks",
        "timestamp": "2024-11-12 05:20:06",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/agenus-agen-reports-q3-loss-132006801.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": false,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ABUS",
    "timestamp": "2024-11-17 14:46:46",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 3.64,
    "priceChange": 0.28,
    "openPrice": 3.68,
    "prevClose": 3.63,
    "dayHigh": 3.68,
    "dayLow": 3.42,
    "volume": 1790300,
    "prevVolume": 1140600,
    "averageVolume": 1057616.6666666667,
    "volumeChange": 56.96,
    "volumeVsAvg": 69.28,
    "recentVolumes": [
      829900,
      778900,
      652400,
      1140600,
      1790300
    ],
    "marketCap": 689750912,
    "fiftyTwoWeekHigh": 4.72,
    "fiftyTwoWeekLow": 1.79,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Arbutus Trial of Combination Therapy for Chronic Hepatitis B Shows 'Promising' Results",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-15 09:27:23",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/arbutus-trial-combination-therapy-chronic-172723608.html"
      },
      {
        "title": "Arbutus\u2019 Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-15 08:02:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/arbutus-imdusiran-achieves-functional-cure-160200820.html"
      },
      {
        "title": "Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-15 08:01:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/arbutus-barinthus-bio-announce-data-160100000.html"
      },
      {
        "title": "Arbutus to Present at Jefferies London Healthcare Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-14 04:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/arbutus-present-jefferies-london-healthcare-123000723.html"
      },
      {
        "title": "Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-06 23:12:14",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/arbutus-biopharma-corp-abus-q3-071214125.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ABCL",
    "timestamp": "2024-11-17 14:46:46",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 2.65,
    "priceChange": -3.99,
    "openPrice": 2.75,
    "prevClose": 2.76,
    "dayHigh": 2.76,
    "dayLow": 2.57,
    "volume": 3269200,
    "prevVolume": 2755500,
    "averageVolume": 1941427.7777777778,
    "volumeChange": 18.64,
    "volumeVsAvg": 68.39,
    "recentVolumes": [
      7642900,
      3999700,
      2667300,
      2755500,
      3269200
    ],
    "marketCap": 782720000,
    "fiftyTwoWeekHigh": 6.05,
    "fiftyTwoWeekLow": 2.33,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024",
        "publisher": "Business Wire",
        "timestamp": "2024-11-07 07:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/abcellera-presents-data-applications-t-150500517.html"
      },
      {
        "title": "AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-07 04:48:55",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/abcellera-biologics-inc-nasdaq-abcl-124855792.html"
      },
      {
        "title": "AbCellera Biologics Third Quarter 2024 Earnings: Misses Expectations",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-06 04:10:32",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/abcellera-biologics-third-quarter-2024-121032057.html"
      },
      {
        "title": "Q3 2024 Abcellera Biologics Inc Earnings Call",
        "publisher": "Thomson Reuters StreetEvents",
        "timestamp": "2024-11-05 08:17:02",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/q3-2024-abcellera-biologics-inc-161702254.html"
      },
      {
        "title": "AbCellera Biologics Inc (ABCL) Q3 2024 Earnings Call Highlights: Navigating Challenges with ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-04 23:11:20",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/abcellera-biologics-inc-abcl-q3-071120036.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": false,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "LOGC",
    "timestamp": "2024-11-17 14:46:47",
    "sector": "Consumer Cyclical",
    "industry": "Internet Retail",
    "price": 6.38,
    "priceChange": 1.59,
    "openPrice": 6.32,
    "prevClose": 6.28,
    "dayHigh": 6.42,
    "dayLow": 6.18,
    "volume": 197800,
    "prevVolume": 183700,
    "averageVolume": 277886.6666666667,
    "volumeChange": 7.68,
    "volumeVsAvg": -28.82,
    "recentVolumes": [
      396100,
      235700,
      211800,
      183700,
      197800
    ],
    "marketCap": 167830368,
    "fiftyTwoWeekHigh": 6.95,
    "fiftyTwoWeekLow": 4.01,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "ContextLogic Third Quarter 2024 Earnings: US$0.038 loss per share (vs US$3.35 loss in 3Q 2023)",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-09 06:00:26",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/contextlogic-third-quarter-2024-earnings-140026710.html"
      },
      {
        "title": "ContextLogic Inc. Reports Third-Quarter 2024 Financial Results",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-07 13:10:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/contextlogic-inc-reports-third-quarter-211000733.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ADVM",
    "timestamp": "2024-11-17 14:46:50",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 6.86,
    "priceChange": -5.38,
    "openPrice": 7.29,
    "prevClose": 7.25,
    "dayHigh": 7.29,
    "dayLow": 6.82,
    "volume": 233600,
    "prevVolume": 204400,
    "averageVolume": 241543.33333333334,
    "volumeChange": 14.29,
    "volumeVsAvg": -3.29,
    "recentVolumes": [
      147000,
      202200,
      124400,
      204400,
      233600
    ],
    "marketCap": 142705152,
    "fiftyTwoWeekHigh": 29.7,
    "fiftyTwoWeekLow": 6.38,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-15 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/adverum-biotechnologies-announces-webcast-report-210500477.html"
      },
      {
        "title": "Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates",
        "publisher": "Zacks",
        "timestamp": "2024-11-04 15:00:06",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/adverum-biotechnologies-advm-reports-q3-230006044.html"
      },
      {
        "title": "Adverum Biotechnologies: Q3 Earnings Snapshot",
        "publisher": "Associated Press Finance",
        "timestamp": "2024-11-04 14:06:37",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/adverum-biotechnologies-q3-earnings-snapshot-220637172.html"
      },
      {
        "title": "Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-04 13:39:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/adverum-biotechnologies-reports-third-quarter-213900316.html"
      },
      {
        "title": "Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-10-16 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/adverum-biotechnologies-appoints-jason-l-120000522.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "SNY",
    "timestamp": "2024-11-17 14:46:50",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "price": 47.97,
    "priceChange": 0.31,
    "openPrice": 47.86,
    "prevClose": 47.82,
    "dayHigh": 48.18,
    "dayLow": 47.46,
    "volume": 3651100,
    "prevVolume": 2973000,
    "averageVolume": 1883260.0,
    "volumeChange": 22.81,
    "volumeVsAvg": 93.87,
    "recentVolumes": [
      2059300,
      2709900,
      1680600,
      2973000,
      3651100
    ],
    "marketCap": 125009829888,
    "fiftyTwoWeekHigh": 58.97,
    "fiftyTwoWeekLow": 45.22,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "How analysts are reacting to RFK Jr. as Trump's HHS pick",
        "publisher": "Yahoo Finance Video",
        "timestamp": "2024-11-15 13:18:51",
        "type": "VIDEO",
        "url": "https://finance.yahoo.com/video/analysts-reacting-rfk-jr-trumps-211851311.html"
      },
      {
        "title": "Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell?",
        "publisher": "Investor's Business Daily",
        "timestamp": "2024-11-15 10:19:01",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/b12eff08-6b54-3777-9f81-ce8b47a4444d/novavax-cut-its-outlook.html"
      },
      {
        "title": "FDA reviews Sanofi and Regeneron\u2019s Dupixent label expansion for urticaria",
        "publisher": "Pharmaceutical Technology",
        "timestamp": "2024-11-15 09:40:31",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/22ab8035-87be-330a-8d88-0b88c489838c/fda-reviews-sanofi-and.html"
      },
      {
        "title": "Stocks to Watch Friday: Applied Materials, Alibaba, Domino's, Novo Nordisk",
        "publisher": "The Wall Street Journal",
        "timestamp": "2024-11-15 09:15:03",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/a3bd1a7e-f5ad-3fb0-aec5-6c42201196f2/stocks-to-watch-friday%3A.html"
      },
      {
        "title": "Trump\u2019s RFK Jr. Pick Weighs on Vaccine Makers",
        "publisher": "The Wall Street Journal",
        "timestamp": "2024-11-15 08:15:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/612b7aaf-0cb7-3cb4-b652-f2235a5bca62/trump%E2%80%99s-rfk-jr.-pick-weighs.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "MRSN",
    "timestamp": "2024-11-17 14:46:51",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 2.21,
    "priceChange": -12.3,
    "openPrice": 2.56,
    "prevClose": 2.52,
    "dayHigh": 2.61,
    "dayLow": 2.21,
    "volume": 1010000,
    "prevVolume": 927300,
    "averageVolume": 1112552.2222222222,
    "volumeChange": 8.92,
    "volumeVsAvg": -9.22,
    "recentVolumes": [
      1440500,
      1519400,
      2879100,
      927300,
      1010000
    ],
    "marketCap": 273007936,
    "fiftyTwoWeekHigh": 6.28,
    "fiftyTwoWeekLow": 1.22,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ...",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-11-13 23:06:13",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mersana-therapeutics-inc-mrsn-q3-070613445.html"
      },
      {
        "title": "Q3 2024 Mersana Therapeutics Inc Earnings Call",
        "publisher": "Thomson Reuters StreetEvents",
        "timestamp": "2024-11-13 22:32:44",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/q3-2024-mersana-therapeutics-inc-063244652.html"
      },
      {
        "title": "Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates",
        "publisher": "Zacks",
        "timestamp": "2024-11-13 05:10:03",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mersana-therapeutics-inc-mrsn-reports-131003104.html"
      },
      {
        "title": "Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-13 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mersana-therapeutics-provides-business-announces-120000709.html"
      },
      {
        "title": "Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-06 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mersana-therapeutics-host-third-quarter-130000065.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "TCRT",
    "timestamp": "2024-11-17 14:46:52",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 2.08,
    "priceChange": -11.11,
    "openPrice": 2.41,
    "prevClose": 2.34,
    "dayHigh": 2.41,
    "dayLow": 2.08,
    "volume": 22300,
    "prevVolume": 8300,
    "averageVolume": 21644.11111111111,
    "volumeChange": 168.67,
    "volumeVsAvg": 3.03,
    "recentVolumes": [
      41400,
      18400,
      36400,
      8300,
      22300
    ],
    "marketCap": 3346612,
    "fiftyTwoWeekHigh": 33.0,
    "fiftyTwoWeekLow": 1.95,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy",
        "publisher": "TipRanks",
        "timestamp": "2024-10-11 05:57:37",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/alaunos-therapeutics-ends-licensing-deal-125737537.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ASRT",
    "timestamp": "2024-11-17 14:46:52",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "price": 0.81,
    "priceChange": -3.57,
    "openPrice": 0.83,
    "prevClose": 0.84,
    "dayHigh": 0.84,
    "dayLow": 0.78,
    "volume": 1026900,
    "prevVolume": 454000,
    "averageVolume": 713876.6666666666,
    "volumeChange": 126.19,
    "volumeVsAvg": 43.85,
    "recentVolumes": [
      2364300,
      1713300,
      734900,
      454000,
      1026900
    ],
    "marketCap": 77470688,
    "fiftyTwoWeekHigh": 1.8,
    "fiftyTwoWeekLow": 0.73,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Assertio Holdings Third Quarter 2024 Earnings: Beats Expectations",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-13 02:27:44",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/assertio-holdings-third-quarter-2024-102744622.html"
      },
      {
        "title": "Q3 2024 Assertio Holdings Inc Earnings Call",
        "publisher": "Thomson Reuters StreetEvents",
        "timestamp": "2024-11-12 06:41:20",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/q3-2024-assertio-holdings-inc-144120676.html"
      },
      {
        "title": "Assertio: Q3 Earnings Snapshot",
        "publisher": "Associated Press Finance",
        "timestamp": "2024-11-11 13:09:12",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/assertio-q3-earnings-snapshot-210912392.html"
      },
      {
        "title": "Assertio Reports Third Quarter 2024 Financial Results",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-11 13:02:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/assertio-reports-third-quarter-2024-210200924.html"
      },
      {
        "title": "Assertio Provides Response to Letter from Short-seller",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-11 04:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/assertio-provides-response-letter-short-123000598.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ABBV",
    "timestamp": "2024-11-17 14:46:53",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "price": 165.02,
    "priceChange": -2.72,
    "openPrice": 169.63,
    "prevClose": 169.63,
    "dayHigh": 169.63,
    "dayLow": 164.72,
    "volume": 11232900,
    "prevVolume": 8442500,
    "averageVolume": 5271577.777777778,
    "volumeChange": 33.05,
    "volumeVsAvg": 113.08,
    "recentVolumes": [
      20760300,
      10557000,
      8483500,
      8442500,
      11232900
    ],
    "marketCap": 291560423424,
    "fiftyTwoWeekHigh": 207.32,
    "fiftyTwoWeekLow": 137.14,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "AbbVie's (NYSE:ABBV) Shareholders Will Receive A Bigger Dividend Than Last Year",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-17 04:49:56",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/abbvies-nyse-abbv-shareholders-receive-124956916.html"
      },
      {
        "title": "Why AbbVie\u2019s (ABBV) Drug Setback Creates A Prime Buy-The-Dip Moment",
        "publisher": "Insider Monkey",
        "timestamp": "2024-11-16 07:08:41",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/why-abbvie-abbv-drug-setback-150841587.html"
      },
      {
        "title": "Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback",
        "publisher": "Zacks",
        "timestamp": "2024-11-15 12:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/pharma-stock-roundup-azn-bayrys-200000075.html"
      },
      {
        "title": "Redburn Atlantic Adjusts AbbVie's Price Target to $216 From $215, Keeps Buy Rating",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-15 09:43:17",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/redburn-atlantic-adjusts-abbvie-apos-174317735.html"
      },
      {
        "title": "AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?",
        "publisher": "Zacks",
        "timestamp": "2024-11-15 07:08:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/abbvie-stock-falls-11-month-150800971.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ADMA",
    "timestamp": "2024-11-17 14:46:53",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 19.03,
    "priceChange": -5.79,
    "openPrice": 20.23,
    "prevClose": 20.2,
    "dayHigh": 20.34,
    "dayLow": 19.02,
    "volume": 3623800,
    "prevVolume": 3216000,
    "averageVolume": 4885444.444444444,
    "volumeChange": 12.68,
    "volumeVsAvg": -25.82,
    "recentVolumes": [
      4840600,
      4186100,
      2440900,
      3216000,
      3623800
    ],
    "marketCap": 4500866048,
    "fiftyTwoWeekHigh": 23.64,
    "fiftyTwoWeekLow": 3.6,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet",
        "publisher": "Zacks",
        "timestamp": "2024-11-15 06:30:13",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/brokers-suggest-investing-adma-biologics-143013069.html"
      },
      {
        "title": "Statutory Profit Doesn't Reflect How Good ADMA Biologics' (NASDAQ:ADMA) Earnings Are",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-15 03:16:26",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/statutory-profit-doesnt-reflect-good-111626983.html"
      },
      {
        "title": "ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?",
        "publisher": "Zacks",
        "timestamp": "2024-11-12 06:15:11",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/adma-biologics-inc-adma-hits-141511648.html"
      },
      {
        "title": "Vericel Stock Sees RS Rating Shoot Higher",
        "publisher": "Investor's Business Daily",
        "timestamp": "2024-11-11 11:06:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/0099c707-e838-3e9f-85a4-657e7cfe7b7a/vericel-stock-sees-rs-rating.html"
      },
      {
        "title": "Are Medical Stocks Lagging  Addex Therapeutics (ADXN) This Year?",
        "publisher": "Zacks",
        "timestamp": "2024-11-11 06:40:10",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/medical-stocks-lagging-addex-therapeutics-144010072.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "RKLB",
    "timestamp": "2024-11-17 14:46:54",
    "sector": "Industrials",
    "industry": "Aerospace & Defense",
    "price": 19.03,
    "priceChange": 9.65,
    "openPrice": 16.99,
    "prevClose": 17.36,
    "dayHigh": 19.48,
    "dayLow": 16.8,
    "volume": 42112600,
    "prevVolume": 45509000,
    "averageVolume": 15180201.111111112,
    "volumeChange": -7.46,
    "volumeVsAvg": 177.42,
    "recentVolumes": [
      27297200,
      25153600,
      121001300,
      45509000,
      42112600
    ],
    "marketCap": 9498309632,
    "fiftyTwoWeekHigh": 22.55,
    "fiftyTwoWeekLow": 3.47,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "SpaceX Rival Secures Key Contract, But Posts Big Earnings Miss",
        "publisher": "Investor's Business Daily",
        "timestamp": "2024-11-15 13:22:27",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/7fcb8e0b-7b5d-38ac-a69d-e3d376b359c7/spacex-rival-secures-key.html"
      },
      {
        "title": "SpaceX Caught a Rocket With \u2018Chopsticks.\u2019 What Will It Try Next?",
        "publisher": "WSJ",
        "timestamp": "2024-11-14 21:01:00",
        "type": "VIDEO",
        "url": "https://finance.yahoo.com/video/spacex-caught-rocket-chopsticks-try-050100041.html"
      },
      {
        "title": "SpaceX Rival Soars On Price Hikes After Q3 Beat, 55% Sales Spike",
        "publisher": "Investor's Business Daily",
        "timestamp": "2024-11-14 13:36:48",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/0579dc3a-d21a-31ca-8376-990a7a62bfe5/spacex-rival-soars-on-price.html"
      },
      {
        "title": "Earnings Update: Here's Why Analysts Just Lifted Their Rocket Lab USA, Inc. (NASDAQ:RKLB) Price Target To US$14.36",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-14 04:59:46",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/earnings-heres-why-analysts-just-125946137.html"
      },
      {
        "title": "Rocket Lab stock up by over 30% on Q3 earnings results",
        "publisher": "Yahoo Finance Video",
        "timestamp": "2024-11-13 12:50:33",
        "type": "VIDEO",
        "url": "https://finance.yahoo.com/video/rocket-lab-stock-over-30-205033834.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  }
]